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ABSTRACT 
 
Jillian Orans: Structural Studies of Pseudomonas aeruginosa PilY1, a Protein Central to 
Infections in Cystic Fibrosis 
(Under the direction of Matthew R. Redinbo) 
 
Pseudomonas aeruginosa is an opportunistic pathogen that is of particular concern to 
people afflicted with Cystic Fibrosis (CF).  Patients with this disease have significantly 
decreased lung function that leads to airway obstruction and recurrent infections, often by 
Pseudomonas.  This constant infection and its resultant lung damage are eventually fatal in 
over 90% of CF patients.  Pseudomonas aeruginosa is known to adhere to and colonize 
human host cells using a protein called pilY1.  This protein has little available functional 
data, but its mediation of host cell infection made it an attractive structural target.  Here, we 
present the three dimensional crystal structure of the C-terminal domain (residues 644-1148) 
of pilY1.  This domain is conserved (23% identity, 45% similarity) with the pilC adhesion 
proteins from both Neisseria gonorrhoeae and Neisseria meningitidis.  The structure is a 
seven-bladed non-canonical β-propeller and crystallized as a dimer in the asymmetric unit.  
The protein contains a variety of interesting structural features, including an extensive β –
strand (13 residues) that is integrated within two distinct β-blades.  Structural analysis of the 
protein led to the hypotheses that certain regions are important in pilY1 function.  Through 
the use of functional assays to test bacterial colonization as well as biophysical methods, we 
were able to pinpoint two areas of the protein that appear to be relevant to its function.  One 
area is an extended loop region located between two β-strands on adjacent blades; the other is 
a calcium binding site found in a short β-turn within a propeller blade.  These regions 
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appear to be necessary to pilY1’s function in twitching motility and pilus formation.  
Knowledge of the nature of these areas could be critical to the design of small molecules to 
inhibit pilY1 activity and hence Pseudomonas aeruginosa bacterial infection. 
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Chapter 1: 
Pseudomonas aeruginosa and its role as an opportunistic pathogen 
 
INTRODUCTION  
 
Pseudomonas aeruginosa is a pathogenic bacterium that is of particular concern to 
people afflicted with cystic fibrosis.  Pseudomonas is an extremely common hospital-
acquired bacterium that can lead to urinary tract infections, pneumonia, and sepsis.  In 
addition, chronic lung infections caused by this bacterium can result in cumulative organ 
damage that is eventually fatal in most patients.  Pseudomonas attacks human cells using a 
pilus, a rod-like extracellular organelle responsible for attachment of the bacterial cell to the 
host cell.  A key component of the pilus is the protein pilY1, which has been shown to be 
necessary for adherence to human cells and is required for pilus biogenesis.  This protein is 
essential for Pseudomonas infections.  PilY1 homologues are found in other infectious 
bacteria, including Neisseria gonorrhoeae and meningitidis.  Thus, elucidating the detailed 
structural basis for pilY1 function would provide novel avenues for treating a wide range of 
bacterial infections. 
PSEUDOMONAS AERUGINOSA 
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Pseudomonas aeruginosa is a rod-shaped, gram negative bacterium that is pathogenic 
to a wide variety of eukaryotic systems [1].  In humans, it is an opportunistic pathogen, only 
infecting tissues in people with compromised immune systems.  This is particularly a 
problem for AIDS patients, patients undergoing chemotherapy, burn victims, and people with 
cystic fibrosis.  Pseudomonas aeruginosa accounts for over 10% of all nosocomial infections 
that are identifiable as bacterial, ranking second only to Staphylococcus aureus among all 
gram negative pathogens, according to data from the National Nosocomial Infection 
Surveillance System encompassing the last decade [2, 3].  It has an incidence of 0.4%; this 
number is even higher in intensive care units [4-9].  It can infect a wide variety of tissues, 
including the eyes, lungs, urinary tract, gastrointestinal system, and skin and soft tissues.  
Hence, Pseudomonas infection is common and is also associated with higher rates of 
mortality from pneumonia in comparison to many other bacterial pathogens [10].  In several 
studies of fatal nosocomial pneumonia infection, 50% of the patients tested positive for 
Pseudomonas aeruginosa; other cases were associated with at least eight other less 
prominent types of bacteria, including   Staphylococcus aureus and Haemophilus influenzae 
[11, 12]. 
 Pseudomonas is an aerobic bacterium that is ubiquitous in the environment.  It is 
found in soil and water, on the surface of plants, and in decaying organic matter.  It is also 
found in many places in the hospital environment, such as sinks, respirators, humidifiers, and 
on the person of medical staff [13].  P. aeuruginosa has minimal nutritional requirements, 
allowing it to grow in numerous and often unexpected environments including distilled 
water, and allowing it to tolerate a wide variety of physical conditions such as extreme 
temperature, high salt, and even antiseptics.  It has been isolated directly from iodophor 
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disinfectant, phenolic germicide, and iodophor antiseptic solutions, and has also been found 
colonizing PVC pipes that had previously been treated with chlorine, phenolic, quaternary-
ammonium, and iodophor disinfectants [14].  
  
Pseudomonas aeruginosa and antibiotic resistance 
 
What makes Pseudomonas aeruginosa such a virulent pathogen is its resistance to a 
broad spectrum of available antibiotics.  It is intrinsically resistant to a number of antibiotic 
families, including the β-lactams, macrolides, tetracyclins, co-trimoxazole, and most 
fluoroquinolones [4].  This resistance is due to a combination of mechanisms including 
multidrug efflux pumps, prevention of entry due to low permeability of the outer membrane 
(even in comparison to other gram-negative bacteria such as Escherichia coli), and efficient 
enzymatic degradation by β-lactamases. [4]. In addition, P. aeuruginosa is capable of 
developing resistance to other families of antibiotics, often benefiting from previous 
exposure.  It can transfer antibiotic resistance (R) plasmids from one Pseudomonas strain to 
another, as well as to E. coli [15].  These plasmids confer resistance to various 
aminoglycosides, including gentamycin, kanamycin, tobramycin, and streptomycin; over 100 
of these plasmids have been decribed [15-19].  There are a limited number of antibiotic types 
that are effective against this bacterium, including antipseudomonal penicillins, 
cephalosporins, carbapenems, and ciprofloxacin, and resistance to these drugs is emerging 
rapidly [20].  In one recent study of 22 patients with nosocomial multi-resistant P. 
aeruginosa infection, six people developed reversion of previous antibiotic susceptibility; in 
some patients this happened in as quickly as a one-day time period [21].  
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Pseudomonas aeruginosa and Cystic Fibrosis 
 
 Pseudomonas aeruginosa is a devastating pathogen in particular to people with cystic 
fibrosis.  Cystic fibrosis (CF) is the most common fatal autosomal recessive genetic disorder 
among people with European ancestry, occurring with a frequency of 1 in every 3000 live 
births [22].  About 30,000 people in the United States and almost 70,000 people worldwide 
are affected by CF.  There is currently no cure for CF; according to the Cystic Fibrosis 
Foundation, the predicted median survival age of patients in the US is 36.5 years.  People 
with CF are prone to chronic lung infections, often due to Pseudomonas aeruginosa.  Studies 
have shown that the bacterium colonizes the cystic fibrosis lung through the use of biofilms 
which form in the thickened mucus [23, 24].  These biofilms are communities of the bacteria 
that attach and form colonies that can grow on a wide variety of biotic and abiotic surfaces.  
This colonization makes clearance difficult and has also been found to contribute to 
antibiotic resistance [25].  A recent study determined that by the age of 3, over 95% of 
children with CF have shown signs of intermittent infection by the bacterium [25, 26].  
Pseudomonas is the major pathogenic cause of persistent lung infections, which result in 
progressive deterioration of the lung function and eventual mortality.   
 
CYSTIC FIBROSIS AND CFTR 
 
 Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein, which is necessary for chloride regulation at the 
epithelial cell surface, as well as regulatory interactions with other channel proteins.  The 
CFTR gene was discovered in 1989; this discovery has been paramount in building a greater 
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understanding of the underlying causes of CF, the mutations associated with the disease, and 
the potential for theraputics.  The CFTR is a cyclic adenosine monophosphate (cAMP) 
regulated member of the ATP-binding cassette (ABC) transporter family of proteins which 
functions as a plasma membrane chloride channel under the regulation of protein kinase A 
(PKA) [27].  The protein is 1480 amino acids and is comprised of a two transmembrane 
regions containing the chloride pore, as well as two intracellular nucleotide binding domains 
(NBDs) and a regulatory domain.  Gating of the channel is dependent on ATP binding; it is 
not yet known whether hydrolysis is also necessary. [28] Activation of PKA regulates 
opening of the pore and facilitates tissue-specific recycling [29]. 
The CFTR protein is found in the epithelial cells lining various organs, including the 
lungs, digestive tract, sweat glands, and urinary tract.  Over 1,000 mutations associated with 
the disease have been identified to date.  These genetic mutations result in a number of 
scenarios which leave the CFTR protein dysfunctional.  They can be frameshift, deletions, 
insertions, or missense mutations, and the resulting alleles have been grouped into five 
classes [30].  Class 1 alleles contain frameshift or nonsense mutations; these result in 
unstable mRNA that is never translated into protein.  Class 2 alleles, including the ∆F508 
mutation located in NBD1 and present in 70% of people with CF [31], result in a misfolded 
CFTR protein that is held and degraded in the ER.  Class 3 alleles code for normally 
processed proteins that contain missense mutations that render CFTR inactive.  Class 4 
alleles contain missense mutations that reduce CFTR’s chloride ion conductivity, attributed 
to a shortened time in which the channel is open or to slower ion movement [32].  In one 
study that characterized several of these mutations, chloride conductance was found to be 
~20 fold lower than in the wild-type protein [33].  Finally, class 5 alleles encode mutations 
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that lead to abnormal mRNA splicing and protein maturation, resulting in fewer CFTR 
proteins with normal activity at the cell surface.  The various types of mutations observed in 
the classes manifest themselves in the form of disease severity, with class 1-3 alleles 
associated with complete dysfunction of the CFTR and rigorous lung and pancreatic 
symptoms, and those of classes 4 and 5 associated with partial protein deficiency and a range 
of milder symptoms [34].   
Mutations in the CFTR cause a host of problems for the epithelial cells and hence the 
organs they line.  In particular, patients with CF have chronic infections in the lungs, causing 
progressive deterioration.  Cystic fibrosis lungs are extremely susceptible to bacterial 
infection, especially by Pseudomonas aeruginosa, as a direct result of the dysfunctional 
CFTR protein in the epithelia.  In mutated CFTR, chloride is not properly transported 
through the pore of the protein, leading to an ionic imbalance in the epithelial cells.  This 
results in thick mucus which lines the lungs, causing airway obstruction and infection due to 
difficulty in clearance.  Mucus clearance is considered an innate primary defense system for 
protection against bacterial infection; the ability to rid the lungs of infected mucus is 
necessary to prevent chronic infection and eventual respiratory failure [35].  The CF lung is 
incapable of effective clearance and as such is exposed to constant bacterial infection and its 
consequences.   
PSEUDOMONAS AERUGINOSA INFECTION 
 
Type III Secretion Systems  
Central to the virulence of P. aeruginosa is the type III secretion system 
(T3SS),which functions by transporting effector proteins into the eukaryotic host cell [36].  
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Effector proteins modify host cell processes allowing colonization of the bacteria and 
avoidance of the host cell immunodefense system [37].  The T3SS comprises of over 20 
proteins and is considered one of the most sophisticated virulence systems in gram-negative 
pathogens [38].  Secretion of proteins through the bacterial envelope is moderated by what is 
known as a “needle complex”.  This complex contains a multi-ring base, anchoring the 
structure to the membrane, and a needle-like projection traversed by a narrow channel 
through which the proteins most likely pass [38].  This needle complex has been identified in 
several types of gram-negative bacteria, including P. aeruginosa [39], and is presumed to be 
the main component of all type III secretion systems.  Needle complexes are responsible not 
only for recognizing substrates so that they are appropriately targeted, but also for delivering 
proteins into target cells at opportune times.  Translocated proteins typically contain a 
secretion signal that remains uncleaved.  It has been proposed that the toxin proteins are 
delivered through the use of “translocator” proteins, which are also secreted and insert 
themselves into the host cell membrane, paving the way for the needle complex to dock onto 
the formed pore or channel to directly deliver the effector proteins [38, 40, 41]. 
Type IV Pili 
 
Pseudomonas aeruginosa adheres to the eukaryotic host cell surface through the use 
of type IV pili.  Pili are rod-like appendages anchored at the cell membrane that are used to 
mediate adhesion and forceful contraction [42].  The majority of the pilus is composed of a 
small repeating structural subunit called pilin.  In P. aeruginosa, this protein is PilA (from 
this point forward, all type IV pilus proteins will be referred to using the P. aeruginosa 
nomenclature unless otherwise stated).  Repeating copies of PilA make up the basic structural 
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unit of the pilus.  Many other functional proteins are located within or associated with the 
pilus structure.  PilB and PilT are NTPases involved in pilus assembly and retraction, 
respectively.  PilQ is a secretin located in the outer membrane that serves as a pore through 
which the pilus passes during extension and retraction. Two proteins are located within the 
inner membrane: PilD serves as a prepilin peptidase, and PilC is thought to interact with pilB 
during translocation and assembly of the pilus.   Associated with but not found within the 
extracellular pilin structure are minor proteins called pseudopilins, including PilE, PilV-X, 
and FimT-U, which have been found to play a part in typeIV pilus biogenesis [42].  Lastly 
there is PilY1, a putative adhesion protein that has been found both extracellularly in 
association with the pilus and in the membrane fraction of the cell [43].    
 
PILY1 
 
Background 
 
 
The pilY1 gene from Pseudomonas aeruginosa was discovered by Richard Alm and 
colleagues at the University of Queensland in 1996 [43].  It was identified at the same time as 
three other previously uncharacterized genes, pilW, pilX, and pilY2, all of which were 
initially implicated in pilus biogenesis.  PilY1 is a large (127 kDa) protein with ~1163 amino 
acids (this value varies between different strains).  As previously stated, fractionation of 
Pseudomonas cells shows that PilY1 is found mainly in the membrane fraction, with a small 
amount seen in the extracellular fimbrial fraction.  Additional experiments indicated that the 
extracellular PilY1 was associated with the pilin subunit protein PilA [43]. 
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Neisseria PilC 
 
When the protein was compared to protein sequence databases [44], Alm noted that 
PilY1 was a significant match to the 110 kDa pilC protein of Neisseria gonorrhoeae.  N. 
gonorrhoeae (gonococci or GC) is also a gram-negative human pathogen that infects 
mucosal surfaces, causing sexually transmitted endocervicitis in women and urethritis in 
men.  GC is also antibiotic resistant; several families of previously effective drugs including 
penicillins, tetracyclines, and quinolones now have limited utility, and this resistance is 
increasing over time [45].  As just one example, there has been greater than a 16% increase 
in ciprofloxacin-resistant GC in all isolates garnered from Sydney, Australia in a span of only 
12 years, from 1990-2002 [46].  To convey the gravity of this epidemic, consider recent 
studies showing HIV transmission rates may be up to five times greater in people with 
gonorrhea, attributed to an increased viral load in genital fluids [47]. 
The PilC protein from N. gonorrhoeae was identified by Jonsson and colleagues at 
Washington University in 1991 [48].  The protein was found to be expressed in the outer 
membrane as well as in purified pili preparations.  Additional experiments found that PilC 
null mutants express dramatically reduced levels of pili, demonstrating that the protein is 
important in pilus biogenesis.  The protein had also recently been identified as the pilus tip 
and the vehicle of adherence to host epithelial cells [49].  In 1995, Rudel and coworkers 
showed that purified PilC from N. gonorrhoeae effectively competes with pilus-mediated 
attachment of the bacteria to human ME-180 epithelial cells [49].   
Both PilY1 and N. gonorrhoeae PilC share significant homology with the PilC 
protein from Neisseria meningitidis.  N. meningitidis (meningococci or MC) is another gram-
negative human pathogen that is responsible for the worldwide meningitis epidemic.  This 
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bacterium is particularly dangerous because of its ability to activate genetic switches that 
affect expression of virulence genes, causing pathogenic and structural variability that allows 
MC to elude administered antibiotics [50].  MC is the leading cause of bacterial meningitis 
and sepsis in the US [51].  Between 1-5 people in every 100,000 become infected, and 10% 
of these will die, with another 10-20% affected by severe disabilities such as hearing loss and 
limb amputation [52]. 
Homology between P. aeruginosa PilY1 and Neisseria PilC proteins is restricted to 
the C-terminal region; Alm defined this region from residue 613 to the C-term of PilY1.  In 
fact, this homology extends to other PilY1 proteins from various bacteria including 
Xanthomonas and Legionella, as well as the PilC proteins from the Neisseria species.  It was 
therefore a logical conclusion that PilY1 would have similar functions to those found for 
PilC. 
Recent cellular adherence experiments provide direct evidence identifying PilY1 as 
the adhesin in Pseudomonas aeruginosa.  Unpublished data from the laboratory of Matthew 
Wolfgang at UNC-Chapel Hill show that PilY1 null mutants cannot adhere to human corneal 
cells that are easily infected by the wild-type bacteria.   These results make PilY1 an 
attractive structural target, both as a means to identify regions of the protein that are 
important for adherence and pilus biogenesis, and to potentially develop a compound that 
could inhibit bacterial infection.   
How does PilY1 function?  What domains of the protein are required for pilus 
adherence?  What are PilY1’s binding partners, and which area of the protein is involved in 
this binding?  Can we identify areas of the protein that are critical for function in either 
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adherence or biogenesis, and hence are potential targets for inhibition?  These are several of 
the important questions I sought to address in the structural determination of PilY1.
 12 
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FIGURE LEGENDS 
 
 
Figure 1.1 Proposed model of the cystic fibrosis transmembrane conductance regulator 
(CFTR).  It is a 1480 amino acid protein composed of a transmembrane region that contains 
the chloride pore, two nucleotide binding domains (NBDs), and a regulatory domain [28].   
 
Figure 1.2 Proposed model for the type IV pilus in Pseudomonas aeruginosa.  The pilin 
subunit, PilA, is shown in purple.  The proposed adhesin PilY1 is shown in red.  PilT and 
PilB, cytoplasmic NTPases, are shown in green and yellow triangles.  Prepilin peptidase PilD 
is shown in olive, and secretin PilQ is shown in blue.   
 
Figure 1.3 The PilC proteins from Neisseria gonorrhoeae and Neisseria meningitidis 
have sequence homology with PilY1 only within their C-terminal domains.  Residue 
numbers indicate the sequence of PilY1; all three proteins are of the same relative size.  
Sequence identity is shown for both domains of the proteins with the N-terminal domain 
shown as transparent and the C-terminal domain as solid.  Alignments were carried out using 
BLAST [44]. 
 
Figure 1.4 Matthew Wolfgang and colleagues (unpublished) have shown that 
Pseudomonas aeruginosa can only infect these human corneal cells if PilY1 is present.  In 
the top panel, WT PAK strain adheres to the host cell.  In the bottom panel, a PilY1 null 
mutant cannot bind to the same cells. 
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Figure 1.1  CFTR model 
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Figure 1.2 Type IV pilus structure model 
 
 
 
 
 
 
 19 
 
 
 
 
 
Figure 1.3 Sequence homology of PilY1 to Neisseria PilC proteins 
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Figure 1.4 PilY1 mediates bacterial adherence to human corneal cells 
 
  
 
Chapter 2: 
 
Cloning, Expression, and Crystallization of C-terminal pilY1 
 
 
 
INTRODUCTION 
 
 
 We acquired genomic DNA from the PAK strain of Pseudomonas aeruginosa for 
amplification of the pilY1 gene through a collaboration with Dr. Matthew Wolfgang, a 
professor of Microbiology and Immunology at UNC-Chapel Hill. This chapter outlines the 
experimental procedures used to clone the gene, produce C-terminal PilY1 protein, 
crystallize the protein, and determine the three-dimensional structure.  Specifically, this 
chapter will include construct design through the use of structural prediction servers, cloning 
of the gene, expression, purification and crystallization of the protein, as well as additional 
biophysical experiments required to characterize the PilY1 protein.  It will also detail the 
process used to solve the crystal structure, including selenomethionine substitution of the 
protein, data collection and reduction, and the data processing used in determination of the 
final structure.  Of particular interest is the successful introduction of three additional 
methionine residues into the C-terminal region of PilY1 such that multiwavelength 
anomalous dispersion methods using selenomethione-substituted protein could be employed 
to determine the structure.  The native PilY1 C-terminal domain contained only five 
methionine residues, which was not enough to obtain phases for 548 residues.  A total of 
eight was required and achieved. 
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CLONING AND EXPRESSION OF PILY1 
 
Structural prediction for Pseudomonas aeruginosa PilY1  
 
 The full length PilY1 sequence (residues 1-1163) was submitted to the program Phyre 
[1] for structural analysis. Phyre, a successor to 3D-PSSM [1], is a protein fold recognition 
server that attempts to predict a protein’s three-dimensional structure and probable function 
based on a database of proteins with known structure. The quality of the matches was 
determined by the expectation value (E-value), which describes the number of alignments 
with the same or better E-value that would occur by chance during a database search.  
Therefore, a lower E-value corresponds to a more confident prediction.  The sequence was 
also submitted to the server in two parts, the N-terminal sequence (residues 1-678) and the C-
terminal sequence (residues 615-1163), chosen based on sequence alignment with the 
Neisseria PilC proteins.  The output from the analysis consisted of prediction of likely 
disordered regions, secondary structural elements, and alignment to homologous proteins of 
known structure. 
 Analysis of the N-terminal region of pilY1 yielded no significant matches.  The 
closest structure predicted to have homology to this region of the protein scored an E-value 
of 23 and a precision estimate of 5%.  The precision estimate is the percentage of sequences 
with an E-value of equal or lesser value that were actually correct homologues; therefore, this 
was not considered to be significant.  However, analysis of the C-terminal region of the 
protein provided several significant matches.  This domain was predicted to be structurally 
homologous to several proteins with known β-propeller folds, such as those of the alcohol 
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dehydrogenase family.  The top match was the quinohemoprotein alcohol dehydrogenase 
from Comamonas testosteroni, with an E-value of 0.014 and 95 % certainty. 
 The alcohol dehydrogenase (PDB ID 1KB0) identified by Phyre as a homologous 
structure is an 8-bladed β-propeller protein. Residues 678-1114 of the C-terminal region 
encompass the β-strands that comprise the predicted β-propeller.  The C-terminal construct of 
PilY1 used in these studies includes all but one beta strand in the first expected β-propeller 
blade and one β-strand in the seventh expected blade. The eighth blade is not predicted in 
PilY1.  In addition, almost all probable regions of disorder for this domain of the protein 
were located in between the predicted β-strands. 
 
Cloning of pilY1 gene 
 
 The pilY1 gene (residues 1-1163) was amplified from PAK strain genomic DNA 
using the following primers: FWD 5’ CATGCCATGGATGAAATCGGTACTCCACCA 
GATCG 3’; REV 5’ ATAGTTTAGCGGCCGCGTTCTTTCCTTCGATGGGGCGCCA 3’ 
(NACF, Lineberger Comprehensive Cancer Center, UNC-CH).  These primers contained 
NcoI and NotI enzymatic restriction sites, respectively, which were used for cloning into the 
pET28b vector (Novagen, San Diego, CA).  The gene was amplified using a combination of 
two specialized PCR systems, the GC Rich PCR System (Roche, Indianapolis, IN) and the 
Expand Long Template PCR System (Roche, Indianapolis, IN).  The PCR reaction contained 
10x Buffer 1 and DNA polymerase from the Expand Long Template PCR System, as well as 
Resolution Solution from the GC Rich PCR System.   
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 Various N- and C-terminal constructs of the PilY1 gene were also cloned into protein 
expression vectors.  The gene was divided into N- and C-terminal halves using the sequence 
homology to Neisseria gonorrhoeae PilC noted by Alm et al upon identification of the pilY1 
gene [2].  Three new constructs were created: the so-called N- and C-terminal constructs, 
comprising residues 1-614 and 615-1163, respectively, as well as a modified N-terminal 
construct that started at residue 31 to omit a predicted signal sequence.  These constructs 
were amplified as described above and are summarized in Table 2.1.  Constructs were cloned 
into both a pET28 vector (N- or C-terminally His-tagged) and a pMALC2xT vector (New 
England Biolabs, Ipswich, MA) modified with a cleavable His-tag (gift of John Tesmer, 
University of Michigan). 
 
Test Expressions of pilY1 constructs 
 
 Constructs were test-expressed in two different E. coli competent cell lines, 
BL21(DE3) Gold and Origami(DE3) cells (Novagen).  The cultures were grown in Luria 
Broth (LB), induced with either 0.1 mM or 1 mM IPTG at an OD600 of 0.3-0.5, and shaken at 
either 15 or 37°C at 210 RPM.  Samples from each culture were taken pre-induction and 
post-induction at 2, 4, and 6-hr time points, as well as after overnight growth. 
 SDS-PAGE analysis of protein expression showed the two C-terminal constructs of 
the pilY1 gene as the only constructs capable of expressing soluble protein.  This observation 
applied to all test conditions.  Growth at 15°C with 0.1 mM IPTG induction yielded slightly 
more soluble protein than other conditions. The amount of protein produced by each of the 
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constructs was nearly equivalent; for ease of purification, we chose to use the construct in the 
pET28a vector. 
 
Expression and Purification of C-terminal PilY1 
 
 The C-terminal fragment of pilY1 in pET28a was transformed into BL21(DE3) Gold 
competent cells (Novagen).  A liter of LB was inoculated with 10 mL overnight culture and 
grown at 37°C to an OD600 of 0.4.  It was then induced with IPTG to a final concentration of 
0.1 mM, the temperature was dropped to 15°C, and expression was allowed to proceed 
overnight.  Cells were collected by gentle centrifugation at 1600g for 20 minutes at 4°C.  The 
resulting pellet was resuspended in 20 mL of Buffer A (20 mM Tris-HCl pH 7.8, 5 mM 
imidazole, 50 mM NaCl, 5% glycerol), and protease inhibitors were added (0.025 mg each 
aprotinin and leupeptin, 0.5 mg PMSF).  Cells were lysed by sonication and clarified by 
centrifugation at 40,000 g for 75 minutes at 4°C. 
 The clarified lysate was loaded onto a 10 mL Probond Ni-affinity column (Invitrogen, 
Carlsbad, CA).  The column was washed twice with 100 mL each of Buffers B and C (same 
components as Buffer A but with 25 and 50 mM imidazole, respectively).  The protein was 
eluted with Buffer D (20 mM Tris-HCl pH 7.8, 75 mM imidazole, 250 mM NaCl, 5% (v/v) 
glycerol).  Fractions were analyzed by SDS-PAGE and concentrated to ~5 mg/mL by 
centrifugation at 4°C, using an Amicon Ultra-15 concentrator with 30K molecular weight 
cutoff (Millipore, Billerica, MA).  The concentrated protein was then further purified using a 
Superose 12 size-exclusion column (Amersham Biosciences, Piscataway, NJ) on an AKTA 
FPLC system (Pharmacia, Uppsala, Sweden), which also facilitated buffer exchange into 
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Buffer A.  The fractions were collected and analyzed by SDS-PAGE, with an estimated 
purity of >95%.  The protein was concentrated to 10 mg/mL in the Amicon Ultra-15 and 
stored at 4°C, or flash-frozen for long-term storage at -80°C.  
 It should be noted that both SDS-PAGE analysis and the sizing column profile 
indicated that the protein was forming an oligomer, presumably a dimer.  The addition of 
DTT as a reducing agent appeared to force the protein into a monomer state as assessed by 
SDS-PAGE, which was indicative of potential disulfide bond formation.  This led to the 
addition of a reducing agent to the protein before crystallization experiments. After 
concentration, TCEP-HCl (Pierce, Rockford, IL) was added to a final concentration of 8 mM.   
 
CRYSTALLIZATION OF PILY1 C-TERMINAL DOMAIN 
 
Initial Crystallization  
 
Initial crystal hits were obtained at the high-throughput crystallization laboratory at 
the Hauptman-Woodward Institute in Buffalo, NY.  This facility utilizes microassay plates to 
screen over 1500 in-house and commercially available conditions using only 0.4 µL of 
protein (10 mg/mL) per drop; the drops are incubated at room temperature under paraffin oil 
and monitored at regular intervals for one month.  After one day, needle crystals of C-
terminal PilY1 were visible in over 60 crystallization conditions.  We were able to reproduce 
twelve of these initial hits at UNC using the hanging drop vapor diffusion method.  
Subsequent improvement of crystal size and quality was achieved by lowering the incubation 
temperature to 15°C and by increasing the protein/crystallant ratio to 2:1.   The condition that 
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produced the most favorable looking crystals contained 0.3 M sodium malonate (pH 6.5) and 
20% PEG 3350.  Use of the Additive Screen (Hampton Research, Aliso Viejo, CA) revealed 
that the addition of 50 mM DTT, 30-100 mM (NH4)3PO4 and 4-8% trifluoroethanol was also 
beneficial to crystallization.  Rectangular-shaped crystals with dimensions of 150x50x50 µm 
appeared overnight; size was improved significantly (up to 10 µm in each direction) when the 
crystals were allowed to grow for a week or more.   
 
Crystal Screening and Data Collection 
 
The crystals were harvested after 1-2 weeks, cryoprotected by short dips in 
perfluoroether oil, and screened in-house at the UNC Biomolecular X-ray Crystallography 
Core Facility, using an RU-type Cu-Kα rotating anode generator and an R-axis IV++ image 
plate detector (Rigaku, Houston, TX).  Crystals diffracted to ~3.0 Å and could be readily 
indexed and scaled using HKL2000 [3]. 
Diffraction data were collected at the Advanced Photon Source at Argonne National 
Laboratory on beamline 22-BM (SER-CAT).  The protein crystallized in the P212121 space 
group and diffracted to a resolution of 2.1 Å.  The data were indexed, integrated and scaled 
using HKL2000 [3].  Data reduction statistics are summarized in Table 2.2. 
 
PHASE DETERMINATION 
 
Heavy Atom Soaks 
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 As no closely related homologous structure was known, we attempted to derivatize 
the crystal by soaking in various heavy atom solutions.  The atoms used were mainly Pt and 
Hg compounds, all from the Hampton Heavy Atom Screen (Hampton Research, Aliso Viejo, 
CA).  The specific compounds, concentrations, and soaking conditions are outlined in Table 
2.3.  Compounds were used at 1, 5, 10, and 50 mM concentrations and soaked for 5, 30, and 
60 minute intervals, as well as overnight.  Crystals were backsoaked in mother liquor for 5, 
30, and 60 minutes, and overnight.  The heavy atoms soaks all proved unsuccessful; although 
several compounds provided an acceptable fluorescence signal (indicative of presence in the 
crystal), no heavy atom sites could be located using customary phasing methods (SOLVE 
[4], SHARP [5], SHELXD/E  [6], and Rantan [7]). 
 
Selenomethionine derivitazation 
 
 After failing to produce a heavy atom derivative through soaking, we decided to 
attempt derivitization of the protein with selenomethionine.  The average protein contains 
one methionine (Met) residue for every 59 amino acids; this is sufficient to provide a usable 
anomalous signal at the appropriate wavelength [8].  Inspection of the protein sequence 
showed that the PilY1 C-terminal construct contained five Met residues out of a total of 548, 
or 1 in ~110, half as many methionines as the average protein.  We suspected that there were 
not enough Met residues in the protein to obtain successful phasing information; 
nevertheless, we decided to carry out the experiment. 
 C-terminal pilY1 in pET28a was transformed into E. coli B834(DE3) competent cells 
(Novagen).  B834 cells are derived from a methionine auxotroph strain; they are unable to 
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produce their own methionine and therefore cannot incorporate the residue into the nascent 
protein chain without supplemented methionine in the growth media.  Therefore, addition of 
selenomethionine to the media as the only source of the Met residue results in the 
incorporation of SeMet instead of Met into the protein.  A 100 mL overnight culture grown 
from a single colony in LB was centrifuged at 40,000 g for 15 minutes, and the pellet was 
washed twice with 50 mL of ddH2O.  This step is critical for removal of any residual 
methionine from the media used in the overnight culture.  The washed pellet was 
resuspended in 1 mL ddH2O.  The cells were then ready for inoculation. 
 To produce the selenomethionine protein, cells were grown in SeMet Medium Base 
minimal media and SelenoMet Nutrient Mix (Athena Enzyme Systems, Baltimore, MD).  
The medium base (21.6 g) was added to 1 L of ddH2O and autoclaved.  After cooling, 5.1 g 
of nutrient mix was dissolved in 50 mL ddH2O; this solution was sterilely filtered into the 
medium base.  After adding antibiotic and supplementing the media with 50-60 mg 
selenomethionine, the 1 mL sample of washed and resuspended overnight culture was added.  
The culture was grown at 37°C to an OD600 of 0.4-0.6, at which time it was induced with 0.1 
mM IPTG and left to shake at 15°C overnight.  The protein was purified and crystallized as 
described for the native pilY1. 
 Crystals of SeMet PilY1 were similar in appearance and diffraction quality to the 
native crystals.  Although the crystals diffracted well enough to collect useful data, 
unfortunately the fluorescence scan did not provide a usable signal (Figure 2.1).  This 
observation led us to believe that the protein did not contain enough methionine residues for 
phasing.  Mass spectrometry analysis (Figure 2.2) confirmed that the protein was 100% 
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substituted with selenomethionine residues in place of methionine; therefore, we decided to 
attempt introduction of additional methionine residues into the protein. 
 Our initial strategy to increase the number of Met residues entailed using sequence 
alignments to find leucine residues in Pseudomonas aeruginosa PilY1 which were aligned to 
methionine residues in homologous proteins (i.e. PilC from Neisseria gonorrhoeae and 
meningitidis).  Leucine is the amino acid most commonly used in methionine replacement.  
After comparing many closely related protein structures, it was determined that leucine was 
the only “safe” residue to use for methionine substitution.  Safe residues were those deemed 
least likely to perturb local protein structure and the overall folding pathway [9].   
Using the sequence alignment, we selected nine Leu residues that aligned with Met 
residues in the homologous Neisseria proteins (L690, L715, L748, L752, L773, L870, L908, 
L990, and L1042).  These residues were mutated using the QuikChange Site-Directed 
Mutagensis Kit (Stratagene, La Jolla, CA) as instructed by the manual.  None of these mutant 
proteins were soluble when expressed in the manner of wild-type PilY1.  This began an 
arduous process in which we selected many leucine residues to mutate, no longer based on 
any sequence homology, and found very few mutant proteins with soluble expression.  In 
addition, some of the stable mutant proteins did not crystallize; of the ones that did, some 
would not crystallize upon selenomethionine substitution.  A summary of the mutant proteins 
and the behavior they exhibited is shown in Table 2.4.  Possible explanations as to why many 
of the Leu to Met mutations were so detrimental to the stability of the protein will be 
discussed in the following chapter. 
Of the 22 mutants tested, we found a combination of 3 additional methionines (L→M 
712, 812, and 823) which yielded soluble protein and crystallized as selenomethionine 
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substituted protein.  In this manner we were able to solve the crystal structure of C-terminal 
PilY1.   
 
Phasing of C-terminal PilY1 using SeMet SAD 
 
 The three dimensional structure of the C-terminal domain of PilY1 was determined 
through the use of selenomethionine single wavelength anomalous dispersion methods 
(SAD).   Crystals with three additional Met residues were grown from SeMet substituted 
protein as described above.  Crystals were similar in appearance to the native crystals; some 
of them were larger and displayed sharper and cleaner faces and edges.   
 Diffraction data were collected at the Advanced Photon Source at Argonne National 
Laboratory, beamline 19-ID (SBC-CAT).  The protein crystallized in the space group C2 and 
diffracted to 2.8 Å.  A fluorescence scan at the selenium peak wavelength showed excellent 
anomalous signal (Figure 2.3).  Data were collected at one peak wavelength (0.979 Å) for 
360° in 0.5° wedges, with little radiation decay observed.  Data reduction, heavy atom 
search, and phase determination were all carried out using HKL3000 [10].  It is worthwhile 
to discuss HKL3000.  This program is the successor to HKL2000 and not yet commercially 
available- by sheer luck we were granted access through a chance meeting with the authors.  
HKL3000 has been used to take raw diffraction images through to a 70% complete model in 
the span of 10 minutes (provided the resolution is 2.3 Å or better).  The program combines 
several available programs to accomplish this feat.  Data indexing, integration, and scaling is 
carried out with HKL2000; a heavy atom search is done with SHELXD/E; phasing and initial 
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phase improvement is carried out with MLPHARE [11], DM [11], FINDNCS [12], and 
SOLVE/RESOLVE; finally, preliminary model building is done with ARP/wARP [13] 
 The protein crystallized as a dimer in the asymmetric unit.  HKL3000 was able to 
locate 14 out of 18 selenium atoms in the asymmetric unit; two of the missing atoms were 
within the first residue of the construct and two were in a disordered region that could not be 
modeled.  ARP/wARP correctly built ~30% of the initial model, and further model building 
was done using COOT [14].  Once 80% of the residues were built, the structure and native 
phases were submitted to MOLREP for molecular replacement [11].  Refinement of the 
native structure was done using maximum likelihood restraint methods with CCP4 [11] and 
CNS [15].  Data reduction, phasing, and refinement statistics are summarized in Table 2.5.  
Analysis of the structure is discussed in greater detail in the following chapter. 
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FIGURE LEGENDS 
 
 
Figure 2.1 The fluorescence scan (left) shows a weak peak at the selenium absorbance 
wavelength, while the scattering factor analysis does not provide usable information for 
determination of SAD x-ray collection wavelengths. 
 
Figure 2.2 The mass spectrometry analysis shows that selenomethionine is fully 
substituted for methionine in the protein used for crystallization. 
 
Figure 2.3 This scan is from the crystals that were used to obtain phasing information.  
The protein used for crystallization had an additional three methionine residues in 
comparison to the wild-type PilY1.  Note the strong peak at the characteristic selenium 
absorption wavelength, and the clear peaks in the scattering factor plot, which provided a 
wavelength for data collection with the maximum anomalous signal.    
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Table 2.1 Summary of pilY1 constructs created for test expression 
 
Construct Vector Restriction 
Sites 
Primers (5’-3’) 
1-612 pET28b NcoI/NotI F:CATGCCATGGATGAAATCGGTACTCCACCAGATC  
R:TTTTCCTTTTGCGGCCGCGCGGTCCTGGCCCTTGGT 
1-612 pMALC2xT EcoRI/XbaI F:GGAATTCATGAAATCGGTACTCCACCAGATC 
R:CTAGTCTAGATTATTAGCGGTCCTGGCCCTTGGT 
31-612 pET28b NcoI/NotI F:AAGGAGATATACCATGGGCCGCCCTGTCGGTCAGC 
R:GCTGACCGACAGGGCGGCCCATGGTATATCTCCTT 
31-612 pMALC2xT EcoRI/XbaI F:GGAATTCATGGGCCGCCCTGTCGGTCAGC 
R:CTAGTCTAGATTATTAGCGGTCCTGGCCCTTGGT 
613-1163 pET28a NdeI/NotI F:GGAATTCCATATGGTGGCCTTCCTGCGCGGCGA 
R:ATAGTTTAGCGGCCGCTTATTAGTTCTTTCCTTCGA 
TGGGGCG 
613-1163 pMALC2xT EcoRI/XbaI F:CCGGAATTCGTGGCCTTCCTGCGCGGCGA 
R:CTAGTCTAGATTATTAGTTCTTTCCTTCGATGGGGCGC
CA 
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Table 2.2 Native Data Reduction Statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of Data Collection, Phasing and Refinement 
PilY1 C-terminal Domain 
Data Set Native 
Unit Cell [abc, Å; αβγ, °] a=64.4, b=108.3, c=159.0 α,γ,β=90 
Space Group P212121 
Wavelength [Å] 1.0718 
X-ray Source APS SER-CAT 22-BM 
Resolution [Å] (Highest shell) 50-2.10 (2.18-2.10) 
No. of Reflections [unique] 65477 
Completeness [%] 99.7 (98.8) 
Rsym [%]  8.5 (43.5) 
I/σ  39.7 (6.7) 
Redundancy 13.9 (13.3) 
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Table 2.3  Heavy Atom Compounds used in crystal soaking experiments 
 
 
 
Compound Crystal Reaction Notes Positive Fluorescence Scan? 
K2PtCl4 Dissolves in > 5mM Yes 
(NH4)2PtCl4  Yes 
K2PtCl6  Yes 
K2Pt(NO2)4 Dissolves in > 5mM Yes 
K2Pt(CN)4·XH2O OK in 10 mM Yes 
PtCl2(H2NCH2CH2CH2NH2)  Yes 
K2PtBr6  Yes 
K2Pt(SCN)6  N/A 
K2PtI6  N/A 
(C2H5HgO)HPO2 Dissolves in > 5mM No 
HgCl2  Yes 
Hg(OOCCH3)3 Dissolves in > 1mM Yes 
Ethylmercuricthiosalicylic acid  N/A 
C8H8HgO2  N/A 
HgBr2  N/A 
HgI2  N/A 
Hg(CN)2  Yes 
CH3HgBr  N/A 
CH3HgCl OK in 10 mM Yes 
KAu(CN)2 Dissolves in > 5mM No 
NaAuCl4 Dissolves in > 5mM No 
HAuCl4  No 
KAuBr4  No 
TlCl3 OK in 10 mM No 
Pb(CH3COO)2 Dissolves in > 1mM N/A 
Pb(NO3)2  N/A 
PbCl2  N/A 
(C2H5)3Pb(CH3COO)2  N/A 
K2IrCl6  Yes 
IrCl3  No 
(NH4)3IrCl6  No 
K2OsO4 OK in 10 mM Yes 
(NH4)2OsBr6 OK in 10 mM No 
K2OsCl6 Dissolves in > 5mM No 
OsCl3 Dissolves in > 5mM No 
TaBr6 OK in 10 mM Yes 
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Table 2.4  Summary of Leucine to Methione Mutations and Results 
 
 
Leu to Met Express solubly? Crystallize? Crystallize with SeMet? 
690 No N/A N/A 
715 Yes No N/A 
748 No N/A N/A 
752 No N/A N/A 
773 No N/A N/A 
870 No N/A N/A 
908 No N/A N/A 
990 No N/A N/A 
1042 No N/A N/A 
712 Yes Yes Yes 
812 Yes Yes Yes 
823 Yes Yes Yes 
762 Yes Yes No 
866 No N/A N/A 
1076 No N/A N/A 
657 Yes Yes Yes 
819 No N/A N/A 
832 Yes Yes Yes 
1029 No N/A N/A 
1120 No N/A N/A 
1123 No N/A N/A 
1142 No N/A N/A 
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Table 2.5 Data reduction, phasing and refinement statistics 
 
 
 
 
 
 
 
 
PilY1 C-terminal Domain 
Data Set Native SeMet 
Unit Cell [abc, Å; αβγ, °] a=64.4, b=108.3, c=159.0 α,γ,β=90 a=169.8, b=64.9, c=116.6 α=γ=90, β=108.7 
Space Group P212121 C2 
Wavelength [Å] 1.0718 0.9792 
X-ray Source APS SER-CAT 22-BM APS SBC-CAT 19-ID 
Resolution [Å] (Highest shell) 50-2.10 (2.18-2.10) 50-2.80 (2.90-2.80) 
No. of Reflections [unique] 65477 29869 
Completeness [%] 99.7 (98.8) 99.9 (100.0) 
Rsyma [%]  8.5 (43.5) 7.1 (24.4) 
I/σ  39.7 (6.7) 48.6 (9.8) 
Redundancy 13.9 (13.3) 7.8 (7.9) 
MAD Phasing Statistics to 2.8 Å  
Se atom sites in AU (observed/total)  14/18 
Mean Figure of Merit   
     MLPHARE (Highest shell)  0.65 (0.60) 
     After DM (Highest shell)  0.82 (0.41) 
Refinement Summary 
Resolution [Å] (Highest shell) 50-2.10 (2.18-2.10)  
Molecules per asymmetric unit (AU) 2  
No. of protein atoms/AU 7361  
No. of waters/AU 818  
Rworking b [%] 19.6 (23.7)  
Rfree c [%] 23.5 (28.1)  
Average B factor [Å2]   
     Protein 29.5  
     Water 42.3  
RMS deviations   
     Bonds [Å] 0.005  
     Angles [o] 1.37  
Coordinate error estimates [Å]   
     Luzzati 0.23  
     SigmaA 0.15  
Ramachandran [%]   
     Allowed, generous, disallowed 98.6, 1.0, 0.4  
PDB ID code   
a
 Rsym = Σ|I- 〈I〉|/ Σ|I|, where I is the observed intensity and <I> is the average intensity of several symmetry-related observations.  
b
 Rworking = Σ||Fo|-|Fc||/ Σ|Fo, where Fo and Fc are the observed and calculated structure factors, respectively. 
    c
 Rfree =  Σ||Fo|-|Fc||/ Σ|Fo for 5% of the data not used at any stage of the structural refinement. 
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Figure 2.1 Fluorescence scan and scattering factor analysis of wild-type PilY1 
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Figure 2.2  ESI Mass Spectrometry analysis of Selenomethionine substituted PilY1 
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Figure 2.3 Fluorescence scan and scattering factor analysis of triple methionine 
mutant PilY1 
  
 
 
 
 
 
 
Chapter 3: 
 
Structural Analysis of PilY1 C-terminal domain 
 
 
 
 
OVERALL STRUCTURE OF PILY1 C-TERMINAL DOMAIN 
 
 
 
 The overall structure of the PilY1 C-terminal domain is a modified β-propeller.  
Indeed, this overall fold was the structural motif predicted by the bioinformatics program 
Phyre [1].  The PilY1 C-terminal domain (residues 615-1163) crystallized as a dimer in the 
asymmetric unit, both for the selenomethionine substituted protein (space group C2) and the 
native protein (space group P212121).  This shift in space group from the native to the 
derivative crystal entails a reordering of cell constants (a, b, and c become c, a, and b) as well 
as an increase in the β angle (90° to ~109°).  Additionally, the lengths of the a, b and c cell 
constants increased, from 64.4 to 64.9, 108.3 to 116.6, and 159.0 to 169.9 Å, with respect to 
the native structure.  We can hypothesize that the addition of selenium to the methionine 
residues caused a reorganization of the unit cell which required this increase in both the 
lengths of the cell constants and in one of the angles.  Further evidence of this hypothesis is 
provided through generation of the symmetry mates of the two structures in their respective 
unit cells, which show a more tightly packed arrangement of protein molecules in the native 
crystal.   
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Both the monomer and the dimer are shown as color-coded cartoons in Figures 3.1 
and 3.2.  Each monomer is composed of a 7-bladed β-propeller surrounding a central pore, 
with 9 α-helices and 2 additional β-strands interspersed throughout the structure.  The first 
four blades of the propeller each contain four anti-parallel β-strands, but beyond this the 
structure becomes more complex than the canonical β-propeller structures elucidated 
previously.  For example, the fifth blade of the pilY1 C-terminal monomer contains five β-
strands; however they are not sequentially contiguous.  After the first three stands of Blade 5 
comes the fifth strand, which also serves as the first strand in the sixth propeller blade.  This 
particular β-strand is thirteen residues long and thus is able to twist in such a way as to 
integrate itself into two adjacent propeller blades (Figure 3.3).  This strand leads into the next 
strand of Blade 6, followed by strand four of Blade 5, which completes this blade for a total 
of five strands.  This is followed by the five strands of Blade 6 (for a total of six strands), and 
finally the three-stranded anti-parallel propeller blade 7.  This complex structural 
arrangement is illustrated in the topology diagram in Figure 3.4.   
In spite of Phyre’s overall success in predicting the general fold of the pilY1 C-
terminal domain, the details of this novel structure were difficult for this suite of programs to 
identify.  For example, a structural alignment of the pilY1 C-terminal domain with the 
quinohemoprotein alcohol dehydrogenase (QAD) from Comamonas testosteroni, a protein 
predicted to be homologous by Phyre, superimposes poorly, with a Cα rms deviation of 15.1 
Å despite the same structural motif (Figure 3.5).  This is due to the presence of β-strands of 
various lengths within the same blade found in the pilY1 structure.  While the QAD propeller 
possesses a set of highly symmetrical blades with four β-strands in each, the pilY1 C-
terminal domain has extremely variable blades (with 3, 4, 5, and 6 strands) and considerably 
 46 
longer β-strands.  This lack of symmetry is especially evident in strand 5 of the fifth blade, 
which as stated previously is a part of two distinct propeller blades and is located far on the 
outside of the canonical motif exemplified by the dehydrogenase.  Hence, although the first 
four blades of pilY1 superimpose well with QAD, the more non-traditional blades (Blade 5 
and beyond) are not capable of alignment.    
 Each monomer is missing two small stretches of amino acids that could not be placed 
into the electron density.  In the N-terminal region of the model, monomer 1 (chain A) is 
missing residues 714-720, while monomer 2 (chain B) is missing residues 712-722.  
Interestingly, this area of the protein was identified as potentially unstructured and 
susceptible to proteolysis through the use of a chymotrypsin digest, which revealed a 
proteolytic site at residue 721.  Briefly, the C-terminal region of pilY1 (61 kD) was subject to 
limited proteolysis using both trypsin and chymotrypsin from bovine pancreas (Sigma). 
Varying amounts (0.5-2 µL) of protease at 40 µM were added to 20 µL of 16 µM C-terminal 
pilY1 in 0.1 M (NH4)HCO3. The reactions were carried out at room temperature for 15 
minutes, quenched with 2 µL of 50 mM PMSF (Sigma), and analyzed by SDS-PAGE.  The 
reaction containing the greatest amount of chymotrypsin produced a single band with a 
molecular weight of ~47 kD and was subsequently analyzed by electrospray ionization mass 
spectrometry (WM Keck Facility, Yale University).  The mass spectrum showed a prominent 
peak at 46.5 kDa.  The cleavage site was located using this mass, knowledge of standard 
chymotypsin cleavage sites (Phe, Tyr, and Trp residues), and the protein analysis software 
PAWS (Protein Analysis WorkSheet, Genomic Solutions, AnnArbor, MI).  PAWS is a 
program that facilitates idntification of proteins and cleavage sites by highlighting potential 
proteolysis products using the protein sequence and results of mass spectrometry analysis.  In 
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this manner we were able to determine the region of the protein found in the mass spectrum 
and hence the cleavage site.  In addition, a second region of missing amino acids was located 
from residues 1062-1068 in both monomers.  Aside from these, the structure is contiguous, 
missing only residues from both the N- and C-termini: residues 615-643 and residues 1149-
1163 cannot be placed in the model. 
 
STRUCTURAL CHARACTERISTICS 
 
β-propeller structural motifs 
 
β-propeller proteins are characterized by extreme sequence diversity and function 
despite similar overall three-dimensional structures [2].  The modular building block of these 
proteins is a four-stranded β-sheet repeated 4-8 times around a central axis [2].  Modular β-
sheets from distinct structures of β-propeller proteins superimpose with rms deviations from 
0.9-2.9 Ǻ [3-8].  Due to the high sequence divergence among these proteins, alignment is 
only possible through superposition of the structures.  In addition, β-propeller proteins have a 
wide range of biological functions and exist in organisms with distinct phylogenetic origins 
[2].  β-propeller proteins have been implicated in many diseases, such as cancer, 
Alzheimer’s, Huntington’s, and osteogenesis, and have different functions that include 
catalysis, scaffold formation, signaling, ligand binding and transport, and mediation of 
protein-protein interactions [9].  Most known β-propeller domains bind ligands or interact 
with other proteins or molecules through the use of the central cavity, found in the center of 
all of the propeller blades [4, 10].  Binding can also occur through variable loops found on 
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the outside of the propeller.  The sequence and length diversity found in both the loops and 
strands of these proteins allow for a stable scaffold with loops that create versatile binding 
surfaces [9].    The only aspect of the β-propeller protein that is consistent among the various 
known structures is the presence of hydrophobic residues located in the central part of the β-
strands that make up the modular sheets.  These residues are important for folding and 
packing in propeller assembly [9]. 
 
WD-40 repeat proteins 
 
One of the largest groups of conserved β-propeller proteins is the WD-repeat protein 
family.  WD-repeat (or WD-40) proteins are characterized by conserved domains of ~40-60 
residues that contain a glycine-histidine (GH) pair towards the N-terminus of the protein, and 
end with a tryptophan-aspartate (WD) dipeptide at the C-terminus.  These proteins can 
contain from four to sixteen of these repeats, with most WD-40 repeats possessing at least 7 
[11].  WD-40 proteins have no known catalytic function and are mainly involved in protein-
protein interactions.  They also possess a wide variety of functions, ranging from signal 
transduction, apoptosis, chromatin assembly, and cell cycle control [11-13].  The WD-40 
proteins are conserved in many species of both prokaryotes and eukaryotes, and have been 
implicated in a number of human diseases, including  lissenceephaly, Cockayne syndrome, 
and Triple-A syndrome [11].   The repeating units of the WD proteins are believed to serve 
as a scaffold for protein-protein interactions and coordination of multiprotein complex 
assembly [13]. 
 49 
To date, there are only eight structures in the Protein Data Bank of WD-40 proteins 
bound to peptides of an interaction partner.  These structures are of two human proteins, the 
Groucho/TLE corepressor bound to two repressor protein fragments, and the WDR5 protein 
which recognizes methylated histone proteins [14-18].  In these structures, the peptide 
fragments are bound within the shallow groove of the central cavity of the β-propeller, in 
direct contact with three or more of the propeller blades.  The WD-40 protein interaction site 
makes the C-terminal domain of PilY1 especially interesting.  Although pilY1 is not known 
to have catalytic activity (similar to many β-propeller proteins), it also lacks an obvious 
protein interaction surface.  When superimposed with the WDR5/Histone 3 peptide 
structures, it is obvious that PilY1 contains two α-helices that cover the central cavity of the 
propeller and completely occlude the binding of any type of ligand at this surface.  This 
observation is clearly illustrated in Figure 3.6.  Thus, if the PilY1 C-terminal domain does 
mediate protein-protein interactions, it is likely that they occur at a site distinct from this 
more canonical surface. 
 
Location of methionine mutants in the structure 
 
 Recall that 5 of 22 Leu-Met mutants introduced into the pilY1 C-terminal domain to 
provide phasing power led to unstable or uncrystallizable protein variants (see Chapter 2).  It 
was not clear prior to structure determination why the majority of the leucine to methionine 
mutations tested were so detrimental to the stability of pilY1.  The mutations generated are 
mapped out on the PilY1 model in Figure 3.7.  Most of the unsuccessful mutations that 
resulted in expression of insoluble protein were found within β-strands of propeller blades.  
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As stated previously, conserved hydrophobic residues are often the only characteristic that β-
propellers have in common.  Because sequence diversity among these proteins is so great, 
recognition of conserved core hydrophobic residues can be a valuable tool when attempting 
to identify other proteins with this fold that lack obvious sequence repeats, such as those in 
the WD40 family [19].  These observations appear to explain why mutation of most of the 
conserved leucine residues from other bacterial PilY1 homologues was deleterious to the 
stability of the protein.  However, two of the acceptable mutations were also found within β-
strands.  Of these two mutants, one is located on the outermost strand of a propeller blade 
(L832 of Blade 3), while the other is found at the very tip of the β-strand (L762 of Blade 2).  
These mutants are located at more peripheral locations, rather than at the core of the 
propeller.  They also seem to have fewer interaction partners than some of the other 
deleterious mutants that are located in central strands or adjacent to outer loops that may be 
supported by the propeller structure.  This observation could explain why the changes were 
not destabilizing as were many of the other intra-strand mutations.   
 
PilY1 C-terminal domain is an incomplete β-propeller 
 
 A cursory inspection of the PilY1 model reveals that the structure does not form a 
complete β-propeller.  There is a large opening (~24 Ǻ at the widest point) between the first 
and seventh blades of the propeller; this is more than enough space to accommodate another 
complete blade.  This does not appear to be an error of protein construct design the isolation 
of this domain from the full length PilY1 for structural analysis.  BLAST sequence 
alignments with other bacterial PilY1 homologues show that all homology starts within the 
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C-terminal construct employed for these studies.  As this is a conserved region of these 
proteins, one would assume that the homology would encompass the entire structural motif.   
 This assumption is further justified from inspection of the structure of the receptor 
binding protein P2 of bacteriophage PRD1 [20].  The PRD1 viron can infect a broad range of 
gram-negative bacteria, and P2 is thought to be responsible for recognition and attachment 
during infection [20].  The protein contains two domains, termed the head and the tail, which 
are composed of a “pseudo” β-propeller and extended loop/β-strand region, respectively, and 
come together to resemble a seahorse.  A superposition of the P2 protein with C-terminal 
PilY1 is shown in Figure 3.8.  The authors refer to the head domain of the protein as a 
pseudo β-propeller for two reasons: first, there is little sequence identity or conservation 
between blades (sequence identity does occur between blades in WD-repeat proteins; see 
Figure 3.9), and second, the topology of the blades does not exhibit classic propeller 
symmetry.  These features are also found in the C-terminal domain of PilY1.  Another 
similar feature of the P2 model is the location of two short helices, which cover the central 
binding cavity that serves as an interaction surface in many other propellers.  It is proposed 
that P2 uses either large outer loops or the open groove in the β-propeller as the region for 
protein-protein interactions.  Interestingly, both the P2 and PilY1 structures contain a calcium 
binding site, which will be discussed in detail below.  Taken together, these observations 
indicate that both infectious bacteria and viruses employ modified β-propeller-containing 
proteins to mediate host cell attachment and entry.   
 
Calcium binding site 
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 The C-terminal domain of pilY1 contains a single calcium binding site located within 
a β-hairpin turn between the first and second strands of the fourth propeller blade.  The 
calcium binding site is shown in Figure 3.10.  The calcium ion is coordinated by seven 
ligands: five side chain oxygens on three Asp and one Asn residue (D851, N853, D855 and 
D859; the interaction with D859 is bidentate), as well as the main chain carbonyl oxygen of 
V857 and one water molecule.  Identity of the nature of the metal ion was determined 
through analysis of the number, nature and distance to the metal ion for all ligands involved.  
A summary of these distances is given in Table 3.1.  All distances are well within agreement 
of the values found in the Cambridge Structural Database as well as the Protein Data Bank 
[21].  The three Asp residues are conserved among PilC from both N. gonorrhoeae and 
meningitidis, while the Asn residue is replaced by another Asp.  This alignment is shown in 
Figure 3.11. 
 Calcium is a versatile intracellular signaling ion that is involved in a wide array of 
cellular processes, including fertilization, differentiation and proliferation, and apoptosis 
[22].  Many calcium binding proteins possess a domain known as an “EF-hand” that binds 
the metal ion.  The domain consists of a calcium binding loop that is flanked on both sides by 
a two α-helices.  This motif is found in a large number of Ca2+ binding proteins, including 
troponins, parvalbumin, and calmodulin [23].  The EF hand motif is often identified through 
sequence analysis.  In this motif, the calcium ion is coordinated by side chain oxygen atoms 
from residues 1, 3, 5, 9, and 12 in the loop, and the carbonyl oxygen of residue 7.  Recently 
sequence analysis of various integrin proteins has shown that the conservation of these 
residues is not enough to presume the type of structure in which the calcium is bound [23].  
Integrins are cell adhesion receptors that are involved in cell-extracellular matrix and cell-cell 
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adhesion interactions. Although the integrins have always been predicted to have a calcium 
binding site with an EF hand motif, a more sequentially similar calcium binding site was 
found in a β-hairpin turn of an alkaline protease from P. aeruginosa [24].  This insight was 
confirmed through determination of a crystal structure of integrin αVβ3, which contains in 
part a β-propeller with four calcium binding sites, all found in β-hairpin loops of four 
different propeller blades [25].  The positions of residues 1-7 of this motif are very similar to 
those in the EF hand.  However, several differences are evident.  First, the β-hairpin turn 
lacks an acidic residue at position 12 that is characteristic of the EF hand motif [26].  In 
addition, residue 9 is an Asp in only 34% of EF hand proteins, while an Asp is found in this 
position 96% of the time in integrins [26].  Both of these anti-EF hand characteristics are 
found in the PilY1 structure.  The examination of the role this calcium binding site plays in 
PilY1 and Pseudomonas function is presented in the next chapter.   
 
Identification of a surface patch of positive charge 
 
  Generation of an electrostatic potential of the PilY1 C-terminal domain structure 
revealed a large, positively charged area on the concave surface of the protein dimer as 
observed in the crystal.  This surface is shown in Figure 3.12.  The patch is located on each 
monomer and is composed of residues R929, R933, K934, and K970.  We hypothesized that 
this area of the protein is important in pilus binding or other protein-protein interactions.  
R929 is conserved in N. gonorrhoeae, while a Lys replaces the Arg at position 933 in N. 
meningitidis.  Additionally, Lys and Arg residues are found at the equivalent positions of 935 
and 936 in both the Neisseria proteins.  Although this sequence similarity is potentially 
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interesting, only the N-terminal amino acids (~60 residues) are conserved among gram-
negative pilin proteins; the C-terminal region is highly variable and found on the outside of 
the pilus fiber, while the conserved region is packed tightly within the core [27, 28].  
However, this charged region is conserved and could potentially be involved in interactions 
with other pilus proteins. Experimental analysis of these residues by site-directed 
mutagenesis and biophysical characterization is described in detail in the following chapter. 
 
Analysis of domain swap observed in the crystal 
 
 Generation of symmetry mates for the PilY1 C-terminal domain dimer revealed a 
potential domain-swap at the N-terminal end of the structure.  This swapped region 
encompasses the first β-blade of the propeller as well as the first three helices in the protein.  
The presence of an actual domain swap could not be determined directly due to the fact that 
the potential connection between the two monomers was disorder in the crystal structure 
(~712-722, described previously).  Distance analysis of the potential connection between the 
two molecules was carried out and is shown in Figure 3.13.  Calculation of the average 
length of a residue in a straight β-strand in the structure yields a distance of 2.83 Å, or 28 Å 
needed for the ~10 residues missing from the model.  Inspection of the distances required 
leads to the assumption that there is not enough space to accommodate these missing residues 
without the presence of a domain-swap.  Biophysical characterization of this region using 
mutation analysis is described further in the following chapter. 
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FIGURE LEGENDS 
 
 
 
Figure 3.1 This dimer comprises the asymmetric unit.  The interface contains several 
helices and loops as well as close interaction of two beta propeller blades, shown in purple. 
 
Figure 3.2 The seven blades of the beta propeller are color-coded.  An especially 
interesting feature is the outer magenta beta strand, which is found in two different propeller 
blades.  The propeller is open on the right side and is considered incomplete. 
 
Figure 3.3 A 13-residue strand from Blades 5 and 6 (top) twists and encompass two 
separate β-propeller blades. 
 
Figure 3.4 A topology diagram of the PilY1 C-terminal domain simplifies its complex 
tertiary structure.  Each blade is color-coded in the same manner as Figures 3.1 and 3.2.  An 
interesting feature is the sixth blade (shown in magenta), which contains a long strand that is 
also part of the fifth blade. 
 
Figure 3.5 The superposition was carried out using only the β-strands in the propeller 
blades.  Although the predicted structural motif of PilY1 was correct, the superposition is 
poor, with an rmsd of ~16 Ǻ. 
 
Figure 3.6 A. The WDR5 protein bound to a histone 3 (H3) methylated peptide at the 
WD40 interaction site.  B.  Similar view of the pilY1 C-terminal domain.  C, D. 
Superposition of the two models shows that the potential interaction site of PilY1 is covered 
by two helices that occlude binding at the central cavity. 
 
Figure 3.7 This map of the methionine mutants tested shows the soluble expressing 
mutants in green, and the insoluble dysfunctional mutants in red.  Notice that many of the 
unsuccessful mutants are found within β-strands in the propeller blades. 
 
Figure 3.8 The P2 protein contains a partial or “pseudo” β-propeller as does PilY1.   
 
Figure 3.9 The sequence alignments of the first three propeller blades in both WDR5 and 
PilY1 C-terminal domain show strong sequence conservation in the WQD-40 protein, but 
little homology in PilY1.  Identical residues are shown in red; nearly identical residues are 
shown in blue; and conserved residues are shown in green. 
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Figure 3.10 The calcium ion is coordinated by five residues and a water molecule.  It 
makes a bidentate contact with D859.  Distances shown are within good agreement with 
other structures from the Cambridge Database and the PDB.  
 
Figure 3.11 Three of the Asp residues are conserved with the Neisseria pilC proteins, 
while the Asn is replaced with another D.  The Gly residue at position 6 and a hydrophobic 
residue at position 8 are conserved as well. 
 
Figure 3.12 The positively charges residues are shown in blue, as indicated by the key.  
The patch is located in the lower left have corner of the left monomer, and the upper right 
hand corner on the right monomer. 
 
Figure 3.13 The original PilY1 structure is shown in cyan, and its symmetry mate is 
shown in magenta.  In the close up, the potential domain swap would be connected through 
the magenta spheres and the cyan spheres; the distances between the intramonomer residues 
are not long enough to accommodate the 10 amino acids missing from the structure, hence a 
domain swap is necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
Ligand Distance in structure (Ǻ) Expected distance (±0.2Ǻ) 
D851 2.46 2.36 
N853 2.25 2.36 
D855 2.53 2.36 
D859 (2) 2.46 2.8 (maximum) 
 2.61 2.8 (maximum) 
V857 2.39 2.36 
H2O 2.41 2.39 
 
 
Table 3.1  Actual and expected calcium ion distances to ligands  
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Figure 3.1  PilY1 dimer in crystal structure 
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Figure 3.2 Front and side view of PilY1 C-terminal monomer 
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Figure 3.3 An extensive β-strand (top) encompasses two propeller blades 
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Figure 3.4 Topology of PilY1 C-terminal domain 
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Figure 3.5  Superposition of PilY1 C-terminal Domain with Comamonas testosteroni 
quinohemoprotein alcohol dehydrogenase 
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Figure 3.6 Standard WD-40 interaction site of WDR5 ß-propeller is inaccessible in 
pilY1 
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Figure 3.7  Methionine mutations tested in PilY1 C-terminal domain 
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Figure 3.8 Superposition of C-terminal PilY1 with the receptor-binding protein  
P2 of bacteriophage PRD1 
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WDR5 
 
 
Blade 1 VSSVKF WLASSS LIKIWG FEKTIS 
Blade 2 ISDVAW LLVSAS TLKIWD CLKTLK 
Blade 3 VFCCNF LIVSGS SVRIWD CLKTLP 
 
PilY1 C-terminal domain 
 
Blade 1 TVG     RVYVG   LHG TFAFI  
Blade 2 VVADAFF AWHTVLIGS  GAFALD  KLLWEI 
Blade 3 TVARL GKWAVVTG  ALLIID  LSSPRLA 
 
 
 
 
Figure 3.9 Sequence alignments of WDR5 propeller blades vs. PilY1 propeller 
blades 
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Figure 3.10 PilY1 calcium binding site 
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Figure 3.11 Sequence alignment of calcium binding site with various PilY1 
homologues 
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Figure 3.12 Electrostatic potential of PilY1 dimer 
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Figure 3.13 Analysis of potential domain swap in PilY1 C-terminal domain 
 
  
 
Chapter 4: 
 
Functional and Biophysical Characterization of PilY1 C-terminal Domain Mutations 
 
 
 
 
INTRODUCTION 
 
 
  
 As stated in Chapter 1, no structural or functional data existed on Pseudomonas 
aeruginosa PilY1 when we initiated this project.  Once we obtained and analyzed the three-
dimensional structure of the C-terminal domain, we next wanted to determine the areas of the 
protein that are important for its functions, such as twitching motility, pilus biogenesis and 
retraction, and its interaction with other protein binding partners.  In addition, we wanted to 
determine whether or not the dimer and the domain swap observed in the crystal structure are 
at all relevant to function.  We answered these questions through the use of rational 
mutational analysis applied to specific areas of the protein that were interesting and 
potentially relevant to function.  This chapter focuses on the rationale behind the selection of 
mutants, as well as descriptions and analysis of the results of the functional and biophysical 
methods used to characterize and evaluate these mutations.  Through the use of these 
techniques, we discovered that the calcium binding site found in a β-turn of the protein is 
important for pilus formation and twitching motility.  Binding affinity experiments 
highlighted the residues that are important for coordinating the calcium; the results of these 
experiments mirrored those found through the functional assays.  This
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discovery could be integral to understanding how PilY1 is involved in bacterial colonization 
and infection. 
 
REGIONS OF THE PROTEIN CHOSEN FOR MUTATIONAL ANALYSIS 
 
Positively charged patch  
 
 
 
 We decided to mutate the four residues identified as part of the positively charged 
patch on the surface of the protein.  This region could potentially be involved in binding the 
bacterial pilus or perhaps another protein involved in the Type IV pilus system; this was 
described briefly as a part of the structural analysis (Chapter 3).  The residues we decided to 
mutate were R929, R933, and K934.  As stated previously in Chapter 3, R929 is conserved in 
N. gonorrhoeae, while a Lys replaces the Arg at position 933 in N. meningitidis.  We chose 
to mutate all of these residues to alanine in order to eliminate the charge on the side chain. 
 
Calcium binding region 
 
 The residues involved in the calcium binding site were described in Chapter 3.  These 
residues are D851, N853, D855, and D859.  Another residue, V857, also makes contact with 
the metal through its main-chain carbonyl, but this contact would be difficult to eliminate.  
We mutated each of the other four residues to alanine, again to eliminate interaction between 
the side chains and the calcium moiety.  We also made an additional double mutant, 
D851A/D859A, to assess the impact associated with removal of more than one calcium 
ligand at the same time. 
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Dimer and domain swap residues 
 
To assess whether the crystallographic dimer and the domain swap are of functional 
significance, we designed mutations to disrupt these potential interactions.  To disturb the 
dimer, we designed two variants, each containing mutations of three to four polar or charged 
residues found at the dimer interface; dimer mutant 1 (T655A, K675A, R1093A, and 
Q1094A) and dimer mutant 2 (T655A, K675A, and S1137A). 
 To attempt elimination of the crystallographic domain swap, we deleted ten residues 
(L712-G722) that serve as the connection between the two monomers. 
 
Cloning mutants and mutation of associated residues 
 
 During the initial cloning of the PilY1 gene by our collaborators, three accidental 
mutations were discovered and found to disrupt all of the protein’s measurable functionality.  
These mutations are not found in the construct we used for crystallization.  We decided to 
make the individual mutations as well as mutate some of the surrounding residues in order to 
determine which of these residues caused the loss of functionality, as well as whether or not 
the particular cloning mutation regions were important to the protein’s function. 
 
F670L 
 
This mutation is of a residue found in a ten amino acid helix located in the N-terminal 
region of the protein.  No adjacent residue mutations were attempted. 
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P1012S 
 
 This mutant is found in an extended loop region (17 residues).  As stated in the 
previous chapter, β-propellers that lack a WD40 interaction site often use large, unstructured 
loop regions as a binding interface for protein partners.  Based on this observation we 
hypothesized that this could be an important part of the structure and made several changes 
to test this.  In addition to P1012S, we tested H930A, W965A, W1015A, D1019A, and 
S1021A, also found in this region, to determine the impact of these residues on protein 
function. 
 
V880A 
 
 This mutation is also found in an extended (18 residue) loop region towards the back 
side of the molecule.  In addition to this mutation, we also made P855A, to see if mutating 
this adjacent residue could destabilize the loop and impact protein function. 
 
Mutations not expected to impact function 
 
 As a type of negative control, we tested mutations of two residues in the protein that 
were found in locations not expected to be important to protein function.  One of these 
residues, Y945, is located between the helices that cover the standard WD40 interaction site 
region.  The other, P782, is a residue found on the back face of the protein in a region that 
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was not an obvious target for analysis.  The Y945 residue was mutated to an alanine, while 
P782 was changed to a serine, to mimic the original P1012 cloning mutation. 
 
FUNCTIONAL AND BIOPHYSICAL ANALYSIS OF WILD-TYPE PILY1 AND 
SELECTED VARIANTS 
 
 We used three different experiments to determine the effect each mutation had on 
PilY1 function.  The first experiment measures twitching motility, or the ability of the 
bacteria to translocate and along a surface.  This motility is conferred by the pilus and is 
necessary for the formation of biofilms [1].  As PilY1 and its Neisseria homologue pilC have 
both been implicated in pilus biogenesis (Matthew Wolfgang, UNC, unpublished) [2], this 
assessment is extremely important in assessing the functional effects of mutations in PilY1.  
The other two methods used were Western blotting for detection of PilY1 in Pseudomonas 
whole cell lysate, and SDS-PAGE analysis to detect the presence of PilA, which indicates 
whether or not the PilY1 mutations affect pilus biogenesis. 
 
Methods 
 
 Full length PilY1 was cloned from Pseudomonas aeruginosa genomic DNA into the 
pDONR221 shuttle vector (Invitrogen, Carlsbad, CA).  All mutations in the PilY1 gene were 
made using the Quikchange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA).  After 
the mutations were created and confirmed by DNA sequencing analysis, the PilY1 gene was 
transferred to the pMMB67EH vector [3] using the Gateway Cloning System (Invitrogen, 
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Carlsbad, CA).   This vector is a low copy, broad host range E. coli plasmid used for 
expression of genes in gram-negative bacteria.  The pMMB67EH plasmid with the full length 
PilY1 gene was the mated with three different P. aeruginosa destination strains (wild-type 
PAK strain, PilY1-null background) using the E. coli DH5α/pRK2013 strain, which contains 
the helper plasmid pRK2013 used to aid in the transfer of the PilY1/pMMB67EH plasmid 
into the Pseudomonas destination strains.   
 
Twitching motility assays 
 
 Colonies containing the mutant plasmid in Pseudomonas aeruginosa (PilY1 null 
background), as well as the PAK, PilY1 null, and PilY1 positive control strains, were 
streaked on LB agar plates containing 150 µg/mL carbenecillin and 25 µg/mL Irgacan.  
Plates were prepared for the twitching assay by pouring 5 mL of LB/1% agar and 50 µM 
IPTG in sterile tissue culture Petri dishes (Fisher Scientific, Houston, TX).  Plates were 
permitted to solidify for 5-10 minutes.  The plated bacteria containing the mutant plasmids as 
well as the controls were scraped and stabbed into the middle of the LB/agar plates.  The 
plates were then placed in a tissue culture incubator at 37°C.  The radius of the distance the 
bacteria traveled from the center of the plate was recorded as 3-4 separate measurements at 
24 and 48 hour time points.  The final distance recorded was difference in the average radius 
measured at both time points divided by the time (radius in cm/hr).  Experiments for each 
sample were performed in triplicate. 
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Pilus preparation 
 
 Patched colonies containing each mutant in the PilY1 null background (as well as the 
PilY1 positive control in the Pseudomonas PAK strain) from plates containing 150 µg/mL 
carbenecillin and 25 µg/mL Irgacan were swabbed and spread on LB/agar plates with 50 µM 
IPTG in order to obtain as much bacteria as possible.  Two different clones for each mutant 
were selected.  The plates were incubated overnight at 37°C.  All of the bacteria on the plates 
were scraped with bent Pasteur pipets and resuspended in 1 mL of 0.15 M NaCl and 0.2% 
Formaldehyde.  The tubes were vortexed on high for one minute and centrifuged at 16,000 G 
for 5 minutes.  After spinning, 450 µL of the supernatant was transferred to a clean 
microfuge tube and 50 uL of 1 M MgCl2 was added.  The tubes were incubated either 4 hours 
or overnight at 4°C and then centrifuged at 16,000 G for 15 minutes.  The pellet was then 
resuspended in SDS-PAGE loading dye and electrophoresed on an 18% acrylamide SDS gel.  
The amount of dye was adjusted to match the size of the pellet obtained in the first 
centrifugation step.  The presence of pilus was determined by the amount of PilA (17 kDa) 
visualized on the gel. 
 
Presence of PilY1 in Pseudomonas cells 
 
 To determine the presence of mutant PilY1 in Pseudomonas aeruginosa whole-cell 
lysate, single colonies were grown in LB overnight.  The next day, 5 mL of the overnight 
culture was added to 5 mL LB with 50 µM IPTG and shaken at 37°C to an OD600 of 1.  The 
culture was then centrifuged for 10 minutes at 16,000 G and resuspended in SDS-PAGE 
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loading dye.  The samples were electrophoresed on an 8% acrylamide SDS gel, which was 
then subjected to Western blotting, using a PilY1 primary antibody with an HRP secondary 
antibody to detect the presence of PilY1.   
 
Oligomerization state of wild-type and domain swap deletion PilY1 
 
 We wanted to determine the oligomerization state of C-terminal PilY1 in solution for 
two reasons: first, to see if the dimer found in the crystal structure was present in solution; 
and second, to determine whether the domain swap seen in the symmetry-related molecule 
was actually present and not a crystallographic artifact.  To accomplish this goal we used two 
techniques, analytical ultracentrifugation (AUC) and dynamic light scattering (DLS). 
 
Analytical Ultracentrifugation 
 
 The AUC experiment was carried out using three different concentrations of C-
terminal PilY1, ranging from 0.25-0.7 mg/mL (in 20 mM Tris-HCl, pH 7.8 and 200 mM 
NaCl).  Sedimentation equilibrium experiments were performed at 25°C at three speeds (12, 
15 and 21K rpm) for 10-12 hours each, using a Beckman XL-A analytical ultracentrifuge 
with scanning absorption optics (Beckman Coulter, Fullerton, CA) and an An-50 Ti rotor.  
Absorbance measurements were taken every 2 hours at 280 nm.  Baseline absorbance offsets 
were determined by increasing rotor speed to 40K rpm for 4 hours.  Data were analyzed with 
the Origin software package (Microcal, Northampton, MA). 
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Dynamic Light Scattering 
 
 Light scattering experiments were performed at 25°C using a Wyatt DAWN EOS 
multi-angle light scattering system (Wyatt Technology, Santa Barbara, CA) coupled to a 25 
mL Superdex200 size-exclusion column (GE Health Sciences, Piscataway, NJ) on an AKTA 
FPLC (Pharmacia, Uppsala, Sweden).  The two instruments were interfaced with a Wyatt 
Optilab refractometer and Wyatt dynamic light scattering module.  The experiment was 
carried out using 250 µL of C-terminal PilY1 protein at 5 mg/mL in 20 mM Tris-HCl pH 7.8, 
200 mM NaCl, and 50 mM imidazole.  Data were analyzed using Astra software (Wyatt 
Technology). 
 
Fluorescence resonance energy transfer to determine calcium binding constants 
 
 We used fluorescence resonance energy transfer (FRET) to measure the calcium ion 
binding affinity of wild-type PilY1 and each of the calcium ligand mutants (D851A, N853A, 
D855A, and D859A).  Affinity was measured using terbium in place of calcium.  Terbium is 
often used as a calcium substitute for affinity experiments, as it has similar ionic radius and 
coordination properties to those of calcium [5].  In addition, terbium can be excited by the 
tryptophan emission wavelength, and its own emission can be measured upon binding to the 
protein, provided that there are one or more tryptophan residues within a usable Förster 
radius. Literature values of this radius for tryptophan fluorescence are widely varied (from 1 
to 20 Å), thus we decided to carry out the experiment to determine if the Trp residues in the 
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structure were in close enough proximity to the calcium binding site to facilitate energy 
transfer.  
 C-terminal PilY1 was prepared as described in Chapter 2 and dialyzed (to remove 
bound calcium) against 8 L of 10 mM Tris-HCl pH 7.8, 50 mM NaCl, and 20 mM EDTA pH 
8.0, over a 48 hour time period.  The EDTA was then removed by dialysis in 8 L of the same 
buffer, without EDTA for another 48 hours.  To ensure all of the calcium was removed from 
the protein, it was then passed over a Ni-NTA column which had previously been stripped of 
the nickel by using EDTA.  This method has been used to effectively remove stubbornly 
bound metal ions from proteins by capturing the metal on the column [6].   
FRET experiments were carried out at 25°C using a SPEX Fluorolog-3 Research T-
format Spectrofluorometer (Horiba Jobin Yvon, Edison, NJ).  Terbium chloride (TbCl3) was 
diluted in protein buffer (10 mM Tris-HCl pH7.8, 50 mM NaCl) to a working concentration 
of 10 mM.  C-terminal PilY1 (400 µL at 2 µM or ~0.12 mg/mL) was added to the cuvette, 
and terbium was added in increasing concentrations (from 0-90 µM) in 0.2 µL increments.  
The protein was excited at 283 nm, the tryptophan excitation wavelength, and terbium 
fluorescence was measured at 543 nm.  Data were analyzed with SigmaPlot (Systat Software, 
San Jose, CA). 
 
FUNCTIONAL ASSAY RESULTS  
 
Positively charged patch 
 
  
 The R929A, R933A, and K934A were subject to the three functional assays 
(twitching motility, presence of PilY1, and presence of pilus) as previously described.  All 
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three of these variants were capable of wild-type or better twitching motility (Figure 4.1).  
The SDS-PAGE analysis of pilus presence showed that both R929A and R933A produced a 
detectable amount of the pilin protein, while K934A showed no sign of PilA (Figure 4.2).  
Western blot analysis showed PilY1 production was that of wild-type in both R929A and 
R933A, but nonexistent in K934A (Figure 4.3).  The implications of these results, as well as 
the results of these assays for all mutations, are further analyzed in the Discussion section of 
this chapter. 
 
Calcium binding region 
 
 Of the four calcium binding ligand mutants in Pseudomonas, only bacteria harboring 
the N853 variant were capable of twitching like wild-type.  Twitching motility was down in 
both D855A and D859A-containing strains (to about half that of wild-type), while strains 
harboring both D851A and the double mutant D851/859A were not capable of twitching 
(Figure 4.4).  The SDS-PAGE analysis of pilus presence showed that none of these mutants 
produced measurable amounts of the pilin protein (Figure 4.5).  Western blot analysis 
showed small amounts of PilY1 in the whole-cell samples from strains containing the D851A 
and D859A mutants, equal to about half that of wild-type expression.  N853A, D855A, and 
D851/859A variants had very little PilY1 expression (Figure 4.6). 
 
Dimer and domain swap residues 
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 Both of the dimer mutants (dimer mutant 1 [T655A, K675A, R1093A, and Q1094A] 
and dimer mutant 2 [T655A, K675A, and S1137A]) in Pseudomonas were able to twitch like 
the wild-type bacteria; however, the domain swap deletion mutant ∆712-722 was unable to 
do so (Figure 4.7).  SDS-PAGE analysis of the pilus showed that strains containing the dimer 
mutants were also producing wild-type levels of pilus, while the domain swap mutant 
produced none (Figure 4.8).  Lastly, strains harboring the dimer mutants were able to 
produce wild-type levels of PilY1, while the domain swap deletion produced almost none 
(Figure 4.9). 
 
Cloning mutants 
 
 Two of the cloning mutants were fully functional: both F670L and V880A are 
capable of twitching motility (though F670L is down to half that of wild-type) (Figure 4.10) 
and produce wild-type levels of both PilA and PilY1 (Figures 4.11 and 4.12).  The P1012S 
mutation in Pseudomonas is incapable of twitching, and does not produce PilA (Figures 4.10 
and 4.11).  However, it does produce wild-type levels of PilY1 (Figure 4.12). 
 
Cloning-associated mutants 
 
 Most of the variants chosen from the V880 and P1012 regions were able to function 
as wild-type, producing pilus and PilY1 and twitching normally (P885A, H930A, D1019A, 
and S1021A) (Figures 4.13-4.15).  Neither W965A nor W1015A could make PilA or PilY1; 
however W965A was capable of twitching normally, while W1015A could not twitch at all. 
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Mutations not expected to impact function 
 
 Psuedomonas  strains harboring both of these mutants (P782S and Y945A) in are able 
to twitch like the wild-type protein (Figure 4.15).  SDS-PAGE and Western blot analysis 
show they are also able to make both pilus and PilY1, although pilus expression is down in 
Y945A, while PilY1 expression is down in P782S (Figures 4.17 and 4.18). 
 
BIOPHYSICAL CHARACTERIZATION RESULTS 
 
Analytical Ultracentrifugation  
 
Sedimentation equilibrium data for the wild-type PilY1 C-terminal domain 
(absorbance at 280 nm versus radius in cm) were fitted using a non-linear curve fitting 
procedure (Origin software) and an estimated partial specific volume (0.736 cm3/g) to 
determine the weight-average monomer molecular weight and an association constant using 
the equation [7]: 
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where cr is the concentration of the protein at the radial position r, cmon is monomer 
concentration at the reference radius (r0), ω is the angular velocity (radians/second), R is the 
gas constant (8.314 x 107erg·mol-1·K-1), T is the temperature in Kelvin, M is the molecular 
weight of the monomer, v bar is the partial specific volume (mL/g), ρ is the density of the 
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solventin g/mL, Ka is the association constant, and E is the baseline offset.  Ka can be 
converted to KD, the dissociation constant, through the following equation: 
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where b is the path length in cm and ε is the molar extinction coefficient of the protein in M-
1cm-1 (71,300 M-1cm-1) . 
When the data were fit to a single species model, the estimated molecular weight was 
determined as 90.3 kDa, indicating that multiple species and higher-order oligomerization 
were present.  When the known monomeric molecular weight of 61.3 kDa was applied and 
fit to a monomer-dimer model, the variance value (χ2) decreased from 1.3x10-4 to 1.8x10-5 
and the residuals appeared more random, suggesting that this was the appropriate model to 
use.  Analysis using the monomer-dimer equilibrium model yielded a dissociation constant of 
27 µM.  The AUC data, the fit, and the residuals are shown in Figure 4.19. 
 
Dynamic light scattering 
 
 Light scattering was quantified as a second-order correlation function using the Astra 
software.  This function was then subject to a non-linear least squares fitting to determine the 
hydrodynamic radii of the species, and hence the mass.  The theory of light scattering can be 
condensed into the following equation: 
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where R(θ,c) is the excess Rayleigh ratio of the solution as a function of the scattering angle 
(θ) and concentration c (directly proportional to intensity of light scattered), MW is the 
weight-averaged solute molecular weight, A2 is the second virial coefficient in the expansion 
of osmotic pressure, K* is a constant (4π2(dn/dc)2n02/Naλ04), Na is Avagadro’s number, and 
P(θ) is a function which describes the angular dependence of the scattered light (related to 
the root mean square radius).  Expansion of P(θ) gives the equation: 
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where n0 is the solvent’s refraction index, λ0 is the vacuum wavelength of the laser, and rg is 
the rms radius.  The mean square radius can then be calculated for the slope at θ=0 of the 
measured ratios 1/R(θ,c) with respect to sin2(θ/2) using the final equation: 
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where M is the mass of the macromolecule made up of mi elements, and ri is the distance 
between mi and the center of the molecule’s mass M.   
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Peak area analysis showed ~90% recovery of initial sample.  Light scattering and 
refractive index measurements plotted against column volume for both the wild-type protein 
and ∆712-722 C-terminal varaint are shown in Figures 4.20 and 4.21.  Both samples showed 
three different peaks representing three species in the solution, with estimated molecular 
weights of 280, 120, and 60 kDa for wild-type, and 257, 124, and 64 kDa for the variant 
protein.  When compared to the monomer weight of 61.3 kDa, these values correspond to 
tetramer, dimer, and monomer species, respectively.  The percentage of each species was 
determined to be 5, 75, and 25% (for tetramer, dimer, and monomer) in the wild-type sample, 
and 5, 80, and 15% in the deletion mutant. 
 
 
 
Terbium/Tryptophan FRET of wild-type and calcium binding mutants 
 
 
 
 FRET data were analyzed using SigmaPlot.  Fractional change in terbium 
fluorescence at 543 nm was plotted against terbium chloride concentration, and data was fit 
to a Hill equation in order to determine the dissociation constant.  In the Hill equation: 
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θ is the fraction of ligand binding sites filled, [L] is the concentration of the ligand, KD is the 
dissociation constant, and n is the Hill coefficient, which describes cooperativity.  The Hill 
coefficient reflects the minimum number of binding sites in the protein; the actually number 
of sites could be higher than this value, but cannot be directly determined though this method 
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because a lack of complete cooperativity is always present.  These plots are shown in Figures 
4.22-4.26.  Dissociation constants were calculated for wild-type C-terminal PilY1, as well as 
N853A and D855A.  These constants were 31 µM ± 1.9, 52 µM ± 0.8, and 62 µM ± 2.4, 
respectively.  Terbium appeared to bind nonspecifically to both the D851A and D859A 
mutants, and therefore the dissociation constant could not be determined. 
 
DISCUSSION 
 
P782S and Y945 do not impact PilY1 function 
 
An important set of results came from mutations selected as negative controls.  Recall 
that these mutations were introduced into regions of the protein that did not seem to have 
obvious functional importance.  P782 is found in a loop region on the back face of the 
protein, in between the second and third β-propeller blades, while the Y945 residue is located 
at the helices covering the WD40 repeat interaction site that is found in other β-propeller 
proteins.  As predicted, these changes had no functional impact on the protein.  Both variants 
were able to twitch normally, as well as express reasonable levels of pilus (PilA) and PilY1 
in bacteria. 
 
The calcium binding site is important to PilY1 function 
 
The results of both the functional assays and the fluorescence experiments lead us to 
conclude that C-terminal PilY1 calcium binding is necessary to protein function.  This 
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conclusion is drawn specifically from the results of the twitching motility assay in 
conjunction with the determination of calcium binding constants.  Three of the mutants, 
N853A, D855A, and D859A, had a weak impact on twitching when harbored in bacteria.  
The D851A mutant in Pseudomonas is not able to twitch.  Upon determination of 
dissociation constants, the wild-type PilY1 showed the lowest KD (of 31 µM, indicating that 
it possesses the highest affinity for calcium), while the two other mutants capable of binding 
calcium had slightly increased dissociation constants (52 µM and 62 µM for N853A and 
D855A, respectively).  Both D851A and D859A variants were not capable of specifically 
binding calcium.  Taken together, these results show an obvious trend which seems to 
indicate that calcium binding affinity is directly correlated with twitching motility capability.  
As twitching motility is a necessary in the colonization of Pseudomonas biofilms on the cell 
surface, this result is by no means trivial. 
 
Analysis of additional variants 
 
Unfortunately, conclusions about many of the other mutations are not straightforward.  
For example, the residues we selected to mutate in the positively charged patch proved 
inconclusive in functional assays.  Both R929A and R933A were capable of twitching like 
wild-type as well as making pilus and PilY1, possibly indicating that this region is not 
important to PilY1 function as we had originally hypothesized.  However, the K934A mutant 
behaved unusually: it was unable to make a pilus or PilY1 but was capable of wild-type 
twitching motility.  This is an interesting discrepancy which we will attempt to explain later 
on in this chapter. 
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Another interesting set of results are those of the dimer disruption mutants.  Two of 
these changes were mutations in combinations of four residues found at the crystallographic 
dimer interface.  These mutants were created with the intention of destroying this interface to 
see if the dimer was functionally important.  We have independently confirmed the presence 
of the dimer in solution through the use of analytical ultracentrifugation and dynamic light 
scattering.  However, these mutations appeared to have no effect on the functionality of the 
PilY1 in Pseudomonas.  Dimer mutants 1 and 2 resulted in normal twitching and production 
of wild-type levels of pilus and PilY1.  This result does not conclusively show that the dimer 
itself is irrelevant, because it these mutations may be enough to disrupt the interface.  This is 
easily testable and thus these mutants will require further investigation, which will be 
outlined later on in this chapter. 
The other mutant with potential to disrupt an oligomeric interface was the domain 
swap deletion mutant ∆712-722.  This mutant lacked 11 residues that appeare to connect a 
PilY1 C-terminal monomer to a symmetry mate in a suggested domain swap (analyzed in 
Chapter 3).  If the protein is domain-swapped, the removal of these residues could impact the 
oligomerization state as well as functionality of PilY1.  Interestingly, this mutant does not 
perform like the wild-type protein inside Pseudomonas cells.  It could not twitch or produce 
pilin in bacteria, and made very little PilY1.  These results seem to indicate that this region of 
the protein is important to PilY1 function.  However, if this is true, it most likely not related 
to a physiological domain swap.  Light scattering analysis shows that the multimeric profile 
of ∆712-722 PilY1 is the same as that of wild-type.  It is possible that the domain swap is a 
crystallographic artifact; however we are fairly certain that this region is domain-swapped in 
the structure. 
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Mutations associated with the cloning mutations provided a wide and unusual array of 
results.  Although the original cloning mutants (F670L, V880A, and P1012S) were all found 
to be deleterious to the function of Pseudomonas by our collaborators, we found that only 
P1012S did not behave like wild-type.  Although twitching and pilin expression was slightly 
lower than normal in bacteria harboring both F670L and V880A, the P1012S mutant could 
not twitch or make pilus in the bacteria.  Interestingly, this mutant makes wild-type levels of 
PilY1. 
Analyses of the mutations associated with the cloning mutations are for the most part 
straightforward.  Most of the mutants (P885A, H930A, D1019A, and S1021A) are consistant 
with normal twitching and produced wild-type levels of both PilA and PilY1 in bacteria.  
Neither the W965A nor W1015A changes produce PilA or PilY1; however, W965A in 
bacteria could twitch while W1015 could not.  Again, an explanation for this discrepancy 
will be discussed in the following section.  As at least two of these mutations (associated 
with the P1012S mutant) were obviously deleterious to protein function and hence, this 
region of the protein could be functionally relevant.  As previously stated, β-propeller 
proteins that lack a WD40 interaction surface often bind protein partners through the use of 
extended loop regions, of which the P1012S and associated mutants are a part.   
 
Mutations can be functionally divided into four categories 
 
 Analysis of the functional assays data indicate that most of the PilY1 mutations 
created can be categorized into four groups.  The first is the “normal” group (Category I).  
These mutants (Y945A, H930A, R929A, R933A, P782S, D1019A, S1021A, Dimer mutant 1, 
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and Dimer mutant 2) have normal twitching motility profiles and produce wild-type levels of 
both pilus and PilY1 in bacteria.  Both F670L and V880A can also be categorized in this 
manner, despite reduced pilin expression in both and slightly lower twitching in F670L.  
These mutants, and in some cases their surrounding regions, are not central to PilY1 
function. 
 The next category of mutants is Category II, or the “dysfunctional” mutants.  These 
mutations when harbored in bacteria produce little to no PilY1, cannot make a pilus, and are 
not capable of twitching motility.  Mutants that fall into this category are W1015A, the 
double calcium binding mutant D851/859A, and the domain swap deletion ∆712-722.  These 
variants are interesting in the sense that the residues involved are probable very important to 
protein function, however they are also easily understood: no pilus and no PilY1 lead to no 
twitching motility.  In this sense these results are intuitive.  Although both D851/859A and 
∆712-722 produce an extremely small amount of PilY1, the mutations could be destabilizing 
the protein, allowing it expression of a protein lacking function. 
 Category III mutants are mutations that produce near wild-type levels of PilY1 but 
have no function: they cannot twitch and do not make a pilus.  This category includes the 
cloning mutant P1012S and the calcium binding mutant D851A.  Analysis of these mutations 
is problematic; although the PilY1 itself seems to be stable, the mutants do not have any 
associated functions.  Since the Western blotting detection of PilY1 was carried out on whole 
cell Pseudomonas lysate, it is possible that the PilY1 is not being trafficked to the outside of 
the cell (where is would be found at the tip of the pilus) and is thus unable to perform any 
functional duties.  This scenario is also feasible for the Category II mutants.  This hypothesis 
is easily testable, and will be discussed in the future work. 
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 The final category of mutants (Category IV) include those that are A) capable of 
twitching like wild-type and make PilY1 but produce no pilus, or B) can twitch but make no 
pilus and no PilY1.  Category IVA mutants include W965A, N853A, and D859A, while B 
includes K934A and D855A.  It is also interesting to note that both W965A and N853A (4A 
mutants) produce PilY1 that appears to be at a higher molecular weight than that of wild-
type, which we are currently unable to explain.  Although it is possible for Pseudomonas to 
twitch with very few pili (so few that the pilus cannot be visualized on a coomassie-stained 
SDS gel), we assume that these pili-depleted bacteria would not be able to twitch as well as 
the wild-type bacteria.  This category of mutant requires further investigation in order to 
elucidate the mechanism behind the twitching motility. 
 
Future experiments are required to determine mechanisms involved in reduced 
functionality 
 
 More experiments will be necessary to determine the mechanisms behind the 
functional phenomena we have observed in many of these PilY1 C-terminal mutations.  As 
mentioned previously, an obvious experiment is to fractionate the Pseudomonas cells and 
separate them into membrane, periplasmic, cytoplasmic, and extracellular (pilus) fractions.  
This would tell us where the PilY1 in the whole cell lysate was located, and could give 
valuable clues in determining the potential stability of the PilY1 protein- is it being trafficked 
to the proper location, could it be unfolded?   
 Another experiment to measure stability is to determine the melting temperatures of 
the variants through circular dichroism spectropolarimetry and comparing them to that of the 
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wild-type PilY1.  This would tell us which PilY1 mutants are less stable in solution and 
could explain some of the results (specifically, mutants that make PilY1 but cannot produce 
pilus or twitch normally).  We plan on carrying out this experiment with all of the twitching-
dysfunctional mutants to see if the stability correlates with function. 
 More specifically, we would like to investigate whether the observed oligomers of the 
protein in vitro are important to protein function.  As was stated previously, we are not 
certain if we are disrupting the crystallographic dimer to the point of keeping the monomers 
apart.  We have a new dimer disruption construct being created to interrupt all electrostatic 
interactions by adding repulsive charges to five of the interface residues.  Analytical 
Ultracentrifugation or light scattering experiments will be used to see if the dimer is being 
destroyed by the new mutations as well as the older dimer mutant constructs.  We will also 
perform AUC on the domain swap deletion mutant to see if the results agree with those from 
the light scattering experiment. 
 The most exciting results we have acquired are those of the calcium binding residue 
mutations.  We can say with certainty through FRET and the twitching motility assay that 
there is a direct correlation between calcium binding affinity and twitching motility.  We 
would like to pursue these mutants through two additional functional assays.  One of these 
involves the ability of bacteria harboring the mutants to attach to lung epithelial cells.  Recall 
from Chapter 1 (Figure 1.4) that a strains containing wild-type PilY1 adheres to these cells, 
while a PilY1 null mutant was unable to do so.  This is the obvious experiment to determine 
whether or not these mutations have caused the bacteria to lose its infectivity.  In addition, 
we would eventually like to use a mouse model to infect mice with both the wild-type and 
calcium binding mutant PilY1 Pseudomonas to see if the mutants are again unable to cause 
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infection in a living organism.  Proving that the calcium binding site is necessary for PilY1 
function and hence bacterial infectivity is an important goal and is integral to determining the 
mechanism and function of PilY1 in Pseudomonas.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 98 
REFERENCES 
 
 
1. Mattick, J.S., Type IV pili and twitching motility. Annu Rev Microbiol, 2002. 56: p. 
289-314. 
 
2. Pizarro-Cerda, J. and P. Cossart, Bacterial adhesion and entry into host cells. Cell, 
2006. 124(4): p. 715-27. 
 
3. Morales, V.M., A. Backman, and M. Bagdasarian, A series of wide-host-range low-
copy-number vectors that allow direct screening for recombinants. Gene, 1991. 
97(1): p. 39-47. 
 
4. Wolfgang, M., H.S. Park, S.F. Hayes, J.P. van Putten, and M. Koomey, Suppression 
of an absolute defect in type IV pilus biogenesis by loss-of-function mutations in pilT, 
a twitching motility gene in Neisseria gonorrhoeae. Proc Natl Acad Sci U S A, 1998. 
95(25): p. 14973-8. 
 
5. Wilkins, A.L., Y. Ye, W. Yang, H.W. Lee, Z.R. Liu, and J.J. Yang, Metal-binding 
studies for a de novo designed calcium-binding protein. Protein Eng, 2002. 15(7): p. 
571-4. 
 
6. Carrer, C., M. Stolz, E. Lewitzki, C. Rittmeyer, B.O. Kolbesen, and E. Grell, 
Removing coordinated metal ions from proteins: a fast and mild method in aqueous 
solution. Anal Bioanal Chem, 2006. 385(8): p. 1409-13. 
 
7. Noble, S.M., V.E. Carnahan, L.B. Moore, T. Luntz, H. Wang, O.R. Ittoop, J.B. 
Stimmel, P.R. Davis-Searles, R.E. Watkins, G.B. Wisely, E. LeCluyse, A. Tripathy, 
D.P. McDonnell, and M.R. Redinbo, Human PXR forms a tryptophan zipper-
mediated homodimer. Biochemistry, 2006. 45(28): p. 8579-89. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
FIGURE LEGENDS 
 
 
Figure 4.1 The mutants are first shown in the context of the whole protein, with an 
additional close-up shot.  Both the P1012 and V880 residues are located within loop regions, 
while F670L is in a helix. 
 
Figure 4.2 Twitching motility of the Pseudomonas with mutations made in the positively 
charged patch region of the C-terminal domain of PilY1.  When viewed in relation to the two 
positive controls (PAK and PilY1+) the mutants are all capable of wild-type twitching or 
better 
 
Figure 4.3 This figure shows the SDS-PAGE gel bands at 17 kDA, used for detection of 
the PilA protein.  The presence of PilA is used to indicate that the bacteria are producing a 
pilus.  While both R929A and R933A are producing close to wild-type levels of pilin, 
K934A shows no sign of a pilus.  
 
Figure 4.4 This figure shows the Western blot analysis of the positively charged patch 
mutants to see if they could produce PilY1.  When compared to the PAK and PilY1+ 
controls, both R929A and R933A produced wild-type levels of PilY1, while K934A does not 
produce any. 
 
Figure 4.5 The bar graph shows the twitching motility of the Pseudomonas with 
mutations made in the calcium binding region of the C-terminal domain of PilY1.  When 
viewed in relation to the two positive controls (PAK and PilY1+), only the N853 mutant is 
capable of wild-type twitching.  Twitching motility is down to half that of wild-type in both 
D855A and D859A, while D851A and the double mutant D851/859A cannot twitch. 
 
Figure 4.6 SDS-PAGE gel bands at 17 kDA, used for detection of the PilA protein.  The 
presence of PilA is used to indicate that the bacteria are producing a pilus.  None of these 
five mutants are capable of producing pilin. 
 
Figure 4.7 Western blot analysis of the calcium binding mutants to see if they could 
produce PilY1.  When compared to the PAK and PilY1+ controls, both D851A and D859A 
produced about half of the wild-type levels of PilY1, while N853A, D855A, and the double 
mutant (D851/859A) produces almost no detectable PilY1. 
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Figure 4.8 Twitching motility of the Pseudomonas with mutations made in the dimer and 
domain swapped regions of the C-terminal domain of PilY1.  When viewed in relation to the 
two positive controls (PAK and PilY1+), both of the dimer mutants are capable of wild-type 
twitching.  Twitching motility is not seen in the domain swap deletion mutant. 
 
Figure 4.9 SDS-PAGE gel bands at 17 kDA, used for detection of the PilA protein.  The 
presence of PilA is used to indicate that the bacteria are producing a pilus.  Both of the dimer 
mutants are able to produce wild-type levels of pilin, while the domain swap deletion mutant 
does not produce any pilin.   
 
Figure 4.10 Western blot analysis of the dimer and domain swap deletion mutants to see if 
they could produce PilY1.  When compared to the PAK and PilY1+ controls, both the dimer 
1 and dimer 2 mutants produced wild-type levels of PilY1, while ∆712-722 produces very 
little PilY1. 
 
Figure 4.11 Twitching motility of the Pseudomonas with the cloned mutations found in 
the C-terminal domain of PilY1.  When viewed in relation to the two positive controls (PAK 
and PilY1+), both F670L and V880A are capable of near wild-type twitching.  Twitching 
motility is not seen in P1012S. 
 
Figure 4.12 SDS-PAGE gel bands at 17 kDA, used for detection of the PilA protein.  The 
presence of PilA is used to indicate that the bacteria are producing a pilus.  Two of the 
cloning mutants F670L and V880A are able to produce wild-type levels of pilin, while 
P1012S does not produce any pilin.   
 
Figure 4.13 Western blot analysis of the cloning mutants to see if they could produce 
PilY1.  When compared to the PAK and PilY1+ controls, all of the cloning mutants are 
capable of making wild-type levels of PilY1. 
 
Figure 4.14 Twitching motility of the Pseudomonas with mutations associated with the 
cloned mutants found in the C-terminal domain of PilY1.  When viewed in relation to the 
two positive controls (PAK and PilY1+), almost all of the mutants are capable of wild-type 
twitching.  Twitching motility is not seen in W1015A. 
 
Figure 4.15 SDS-PAGE gel bands at 17 kDA, used for detection of the PilA protein.  The 
presence of PilA is used to indicate that the bacteria are producing a pilus.  Two of the 
cloning associated mutants W965A and W1015 are unable to produce wild-type levels of 
pilin, while the rest have normal levels.   
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Figure 4.16 Western blot analysis of the cloning associated mutants to see if they were 
capable of producing PilY1.  When compared to the PAK and PilY1+ controls, all of the 
cloning mutants but W965A and W1015A are capable of making wild-type levels of PilY1. 
 
Figure 4.17 Twitching motility of the Pseudomonas with mutations not expected to impact 
function that are found in the C-terminal domain of PilY1.  When viewed in relation to the 
two positive controls (PAK and PilY1+), both Y945A and P782S are capable of wild-type 
twitching.   
 
Figure 4.18 SDS-PAGE gel bands at 17 kDA, used for detection of the PilA protein.  The 
presence of PilA is used to indicate that the bacteria are producing a pilus.  The two of the 
mutants P782S and Y945A which are not expected to impact function are able to produce 
near wild-type levels of pilin. 
 
Figure 4.19 Western blot analysis of the mutants not expected to impact function, to see if 
they could produce PilY1.  When compared to the PAK and PilY1+ controls, Y945A is 
capable of making near wild-type levels of PilY1, while P782S PilY1 expression is slightly 
lower. 
 
Figure 4.20 The AUC data was collected at 280 nm and fit to a monomer-dimer 
equilibrium model with a dissociation constant of 27 µM.   
 
Figure 4.21 Light scattering analysis was carried out using a multi-angle light scattering 
system in conjunction with a size exclusion column.  The peaks chosen for analysis are 
bracketed by black bars.  Light scattering is shown in red, while the refractive index is shown 
in blue.  The peaks were analyzed and determined to be (left to right) tetramer, dimer, and 
monomer species, with an estimated percentage of 5, 75, and 20%, respectively. 
 
Figure 4.22 Light scattering analysis was carried out using a multi-angle light scattering 
system in conjunction with a size exclusion column.  The peaks chosen for analysis are 
bracketed by black bars.  Light scattering is shown in red, while the refractive index is shown 
in blue.  The peaks were analyzed and determined to be (left to right) tetramer, dimer, and 
monomer species, with an estimated percentage of 5, 80, and 15%, respectively.  This is in 
agreement with the wild-type C-terminal PilY1. 
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Figure 4.23 This graph shows the binding curve of wild-type C-terminal PilY1 and 
terbium chloride, a calcium substitute.  The plot of fractional change in terbium fluorescence 
versus terbium concentration was fit to a three-parameter Hill equation, in which the 
calculated dissociation constant was 31 µM.  This fit gives a Hill coefficient of 2.4 ± 0.3, 
indicating that two binding sites are occupied, or a dimer is present. 
 
Figure 4.24 This graph shows the binding curve of the D851A PilY1 mutant and terbium 
chloride, a calcium substitute.  The plot of fractional change in terbium fluorescence versus 
terbium concentration seemed to show non-specific binding and could not be properly 
analyzed to provide a dissociation constant. 
 
Figure 4.25 This graph shows the binding curve of the N853A mutant PilY1 and terbium 
chloride, a calcium substitute.  The plot of fractional change in terbium fluorescence versus 
terbium concentration was fit to a five-parameter Hill equation, in which the calculated 
dissociation constant was 52 µM. 
 
Figure 4.26 This graph shows the binding curve of the D855A mutant PilY1 and terbium 
chloride, a calcium substitute.  The plot of fractional change in terbium fluorescence versus 
terbium concentration was fit to a four-parameter Hill equation, in which the calculated 
dissociation constant was 62 µM. 
 
Figure 4.27 This graph shows the binding curve of the D859A PilY1 mutant and terbium 
chloride, a calcium substitute.  The plot of fractional change in terbium fluorescence versus 
terbium concentration seemed to show non-specific binding and could not be properly 
analyzed to provide a dissociation constant. 
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Figure 4.1 Locations of cloning mutants in PilY1 C-terminal domain 
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Figure 4.2 Twitching motility of positive charge patch mutations 
 
 
 . 
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Figure 4.3 SDS-PAGE analysis of pilus presence in Pseudomonas aeruginosa with 
positive charge mutants 
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Figure 4.4 Western blots of whole cell Pseudomonas aeruginosa for detection of 
PilY1 in positive charge patch mutants 
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Figure 4.5 Twitching motility of calcium binding ligand mutations 
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Figure 4.6 SDS-PAGE analysis of pilus presence in Pseudomonas aeruginosa with 
calcium binding mutants 
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Figure 4.7 Western blots of whole cell Pseudomonas aeruginosa for detection of 
PilY1 in calcium binding mutants 
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Figure 4.8 Twitching motility of dimer and domain swap mutants 
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Figure 4.9 SDS-PAGE analysis of pilus presence in Pseudomonas aeruginosa with 
dimer and domain swap mutants 
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Figure 4.10 Western blots of whole cell Pseudomonas aeruginosa for detection of 
PilY1 in dimer and domain swap mutants 
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Figure 4.11 Twitching motility of cloning mutations 
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Figure 4.12 SDS-PAGE analysis of pilus presence in Pseudomonas aeruginosa with 
cloning mutants 
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Figure 4.13 Western blots of whole cell Pseudomonas aeruginosa for detection of 
PilY1 in cloning mutants 
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Figure 4.14 Twitching motility of mutations associated with cloning mutants 
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Figure 4.15 SDS-PAGE analysis of pilus presence in Pseudomonas aeruginosa with 
cloning associated mutants 
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Figure 4.16 Western blots of whole cell Pseudomonas aeruginosa for detection of 
PilY1 in cloning associated mutants 
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Figure 4.17 Twitching motility of mutants not expected to impact function 
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Figure 4.18 SDS-PAGE analysis of pilus presence in Pseudomonas aeruginosa with 
mutants not expected to impact function 
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Figure 4.19 Western blots of whole cell Pseudomonas aeruginosa for detection of 
PilY1 in mutants not expected to impact function 
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Figure 4.20 Analytical Ultracentrifugation shows the PilY1 C-terminal domain is a 
dimer           
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Figure 4.21 Dynamic light scattering analysis shows that C-terminal PilY1 is mainly 
found in dimeric form 
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Figure 4.22 Dynamic light scattering analysis shows that C-terminal PilY1 domain 
swap truncation is mainly found in dimeric form 
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Figure 4.23 FRET analysis of wild-type C-terminal PilY1 association with terbium 
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Fractional change in fluorescence vs [Tb3+]
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Figure 4.24 FRET analysis of calcium binding mutant D851A and its association with 
terbium 
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Fractional change in fluorescence vs [Tb3+]
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Figure 4.25 FRET analysis of binding mutant N853A and its association with terbium 
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Fractional change in fluorescence vs [Tb3+]
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Figure 4.26 FRET analysis of binding mutant D855A and its association with terbium 
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Fractional change in fluorescence vs [Tb3+]
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Figure 4.27 FRET analysis of binding mutant D859A and its association with terbium 
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ABSTRACT 
 
The nuclear receptor PXR plays a key but structurally enigmatic role in human 
biology.  This ligand-regulated transcription factor responds to a wide array of chemically-
distinct ligands, including many endogenous compounds and clinical drugs, and regulates the 
expression of a critical set of protective gene products involved in xenobiotic and endobiotic 
metabolism.  The structural basis of this receptor’s remarkable and unique promiscuity is just 
now coming into focus.  We examine the importance of mobile regions novel to the nuclear 
receptor ligand binding domain fold in PXR’s ability to respond to a variety of small and 
large agonists.  We also review the functional roles played by PXR in various biological 
pathways, and outline emerging areas for the future examination of this key nuclear 
xenobiotic receptor. 
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INTRODUCTION 
 
The nuclear pregnane X receptor (PXR; NR1I2, also known as SXR and PAR; [1-3] 
is a member of the nuclear receptor (NR) family of ligand-dependent transcriptional factors 
and a key regulator of genes involved in xenobiotic and endobiotic metabolism. PXR was 
assigned the role of detecting endogenous pregnanes by Kliewer et al.[4], but has 
subsequently been adopted as a central xenobiotic receptor that responds to many clinical 
drugs.  PXR functions as a heterodimer with RXRα and binds to a variety of response 
elements (DR-3, DR-4, DR-5, ER-6, ER-8) in the promoter regions of target genes.   Its 
moderate basal activity and up-regulation of transcriptional events are mediated by 
recruitment of coactivators of the p160 family (e.g., SRC, GRIP); similarly, its repression of 
gene expression involves physical contacts with transcriptional corepressors.  The subcellular 
localization of the receptor between the cytoplasm and nucleus, however, is emerging as an 
important feature in receptor, as are posttranslational modifications and tissue- and ligand-
specific recruitment of transcriptional coregulators.  We review recent advances in our 
understanding of PXR function and structure, and present some key challenges for future 
studies of this nuclear xenobiotic receptor. 
 
PXR FUNCTION 
 
PXR in Xenobiotic and Endobiotic Detection 
 
The cytochromes P450 (CYP450s) are heme-containing mono-oxygenases involved 
in endobiotic and xenobiotic clearance, including the elimination of therapeutic drugs [5]. 
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PXR is expressed predominantly in the liver and is activated by a variety of structurally-
distinct ligands that are known to induce the expression of CYP450 genes central to drug 
metabolism. These compounds include phenobarbital, rifampicin, dexamethasone, nifedipine, 
taxol, and hyperforin, the active agent of the herbal remedy St. John’s wort [3, 4, 6]. Phase I 
drug metabolism genes regulated by PXR include several CYP450s (e.g., CYP3A4, 
CYP2B6, CYP2C8, CYP2C9, and CYP2C19), carboxylesterases, and dehydrogenases, as 
well as enzymes involved in heme production and the P450 reaction cycle [4, 6-13]. Indeed, 
PXR has been termed the master regulator of the expression of CYP3A4, which metabolizes 
more than 50% of human drugs.  PXR also controls the expression of the Phase II drug 
metabolism genes encoding UDP-glucoronosyltransferases and glutathione-S-transferases 
(GSTs), [14-18], and Phase III drug efflux pumps like MDR1 and MRP2 [7, 19-21].  Thus, 
PXR is an important and efficient regulator of the expression of genes involved in all phases 
of drug metabolism and excretion. 
 PXR is also activated by a variety of endogenous ligands, including pregnanes, bile 
acids, hormones, and dietary vitamins [1, 4]. In response to bile acids and oxysterols, PXR 
regulates the expression of genes involved in bile acid metabolism and transport, including 
CYP7A, Oatp2, and HMG CoA synthases [22-24]. These data, and subsequent studies in 
animal models of cholestatic liver disease, have established that PXR plays a critical role in 
cholesterol homeostasis and in protecting tissues from potentially toxic endobiotics [25, 26]. 
 
Species-Specific Activation 
 
 Like most members of the nuclear receptor superfamily, PXR contains a DNA 
binding domain (DBD) connected by a presumably flexible hinge region to a ligand binding 
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domain (LBD), which contains the ligand-dependent activation function (AF-2) region.  
Unlike most nuclear receptors, however, the LBDs of PXRs from different species exhibit 
significant sequence divergence.  For example, mammalian isoforms of PXR share < 80% 
sequence identity within their LBDs compared to >90% within their DBD domains.  
Although each of these PXRs is promiscuous in terms of ligand binding (responding to 
compounds of varying size, shape and chemical composition), each is also relatively specific 
to certain regions of chemical space.  This feature of PXR activation has been termed 
“directed promiscuity”[27].   
Kocarak et al. first noted striking interspecies differences in cytochrome P450 gene 
expression in response to known CYP3A inducers, such as the antiglucocorticoid 
pregnenolone 16-α-carbonitrile (PCN) and the macrolide antibiotic rifampicin [28, 29]. In-
cell trans-species gene transfer studies later determined that the differential CYP3A gene 
expression found in rats, rabbits and humans was not derived from differences in CYP3A 
sequence, but rather from some other factor [30, 31]. After the initial cloning and 
characterization of mouse and human PXR, it was found that both forms of the receptor were 
not only activated by many of the compounds known to regulate CYP3A gene expression, 
but also that they could also bind to response elements in the promoter regions of several 
CYP3A genes. The mouse form of PXR was strongly activated by both PCN and 
dexamethasone [4], while human PXR was efficiently activated by dexamethasone, 
rifampicin, and RU486, another antiglucocorticoid [3, 6].   
Subsequent transient-transfection experiments established that the regulation of these 
genes was dependent upon the activation of PXR, and that the activation profiles of the 
various forms of PXR were remarkably different [31].  For example, rabbit PXR could be 
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activated by rifampicin to induce CYP3A gene expression while rat PXR could not.  
Additionally, equal concentrations of PCN could effectively activate rat PXR, but not the 
rabbit form [31].  Jones et al. expanded these profiles to include human and mouse PXR 
through the use of a novel binding assay.  Rifampicin and SR12813, a cholesterol-lowering 
drug, were found to effectively activate human and rabbit PXR but not rat and mouse forms.  
PCN was found to potently activate mouse as well as rat PXR but have little effect on the 
human and rabbit forms [32].  These data correlated well with the patterns of CYP3A gene 
expression in the liver and intestinal tissues of the various species, proving that the receptor 
has clearly diverged functionally through the process of evolution.  Indeed, several studies 
have identified individual residues in the LBD that confer species-specific transcriptional 
activation to the PXRs [27, 33, 34]. 
 
Cross-Talk with Other Nuclear Receptors 
 
 PXR overlaps functionally with CAR (constitutive androstane receptor) in terms of 
ligand binding and gene activation.  It was noted in 1990 that the treatment of rat hepatocytes 
with phenobarbital caused distinct expression patterns for the cytochrome P450 isoforms 
CYP2B and CYP3A [29]. It was subsequently shown that both PXR and CAR could both be 
activated by phenobarbital, and that the effects of phenobarbital on CYP gene expression 
were mediated by several different nuclear receptors [6].  PXR became established as a 
central regulator of CYP3A genes [1, 3, 4], while CAR was found to respond to 
phenobarbital response elements located on CYP2B genes  [35-37].  In 2000, Moore et al. 
showed that both receptors could be activated by some of the same xenobiotic and endobiotic 
compounds, including rifampicin and phenobarbital [38]. It was then demonstrated that CAR 
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and PXR cross-talk extended to DNA binding, with the finding that PXR could up-regulate 
CYP2B gene products using the same response element employed by CAR, and vice versa 
for CAR’s up-regulation of CYP3A gene products [8].  Thus, PXR and CAR work in concert 
by binding to the same ligands and DNA response elements to control target gene expression.  
Recent studies have established that PXR, CAR and FOXO1, a forkhead transcription factor, 
function together to regulate the expression of a variety of target genes central to drug 
metabolism and gluconeogenesis [39].   
 
Subcellular Localization 
 
 Studies to determine the subcellular localization of PXR have provided conflicting 
results. Two groups have reported that human PXR is consistently localized in the nucleus, 
regardless of the addition of ligand.  In one such study, Kawana et al. used transient 
expression in HeLa cells to show that PXR was localized in the nucleus in the absence of 
ligand [40].  They also identified a nuclear localization signal (NLS) in the DNA binding 
domain of PXR.  Removal of the DBD resulted in solely cytoplasmic localization, and 
mutation of the putative NLS resulted in PXR localization in both the cytoplasm and the 
nucleus.  These results are consistent with immunostaining assays that found human PXR to 
be exclusively located in the nucleus both with and without ligand [41].  Other studies, 
however, have provided evidence to the contrary.  PXR from mouse liver was found to be 
localized in the cytoplasm and translocated to the nucleus only upon addition of PCN or 
other agonists [40, 42].  The discrepancies in these findings may be linked to differences in 
the type of PXR employed (human vs. mouse) or in the in vivo vs. in vitro nature of the 
  137 
experiments. Such results may also indicate that subcellular trafficking is an important 
regulatory process that tunes the function of this nuclear xenobiotic receptor. 
 
Ligand Binding 
 
 The PXRs from a variety of species are all promiscuous and can bind to a variety of 
chemically- and structurally-distinct xenobiotic and endobiotic compounds.  As measured by 
scintillation binding assays [32] and coactivator receptor ligand assays (CARLA, a ligand-
dependent coregulator recruitment assay) [43], PXR is activated by the direct binding of 
ligands within the receptor’s ligand binding cavity [2].  PXR agonists include natural and 
synthetic steroids such as 5β-pregnane-3,20-dione and  estradiol [32],  and xenobiotics like 
the cholesterol drugs lovastatin and SR12813 [6, 32], the anti-cancer drugs tamoxifen and 
taxol [7, 44], the antibiotic rifampicin [1, 6], and the active agent of St. John’s wort, 
hyperforin [45, 46].  These ligands vary widely in shape and chemical features, and range in 
mass from 250 to greater than 800 Da.  Clearly, PXR has a binding promiscuity unlike that of 
any other member of the nuclear receptor superfamily [2]. Crystallographic studies of PXR 
have revealed a novel insert in the ligand binding domain along with a large and conformable 
binding pocket [13, 27, 47].  These structures offer valuable insight into both the promiscuity 
and specificity of the receptor, as discussed below. 
 
Heterodimerization with RXR 
 
Like many other nuclear receptors, PXR controls transcriptional events as a 
heterodimer with RXRα.  PXR is known to bind to at least four distinct DNA response 
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elements, including both direct and everted repeats. Several other receptors that form 
heterodimers with RXRα also utilize both DR and ER response elements, including CAR, 
the vitamin D receptor (VDR), and the thyroid hormone receptor (TR) [48, 49].  Thus, 
because the LBDs of RXRα and these partner receptors are expected to form only one type 
of heterodimer [50], the linkers connecting the DBDs and LBDs of these receptors must be 
flexible in order to bind to distinctly oriented DNA response elements.  It is also possible that 
alternative DNA binding modes may influence coregulator recruitment and transcriptional 
activity in a ligand- and/or tissue-specific manner, providing another level of regulation of 
PXR action [51].   
 
Coregulator Binding 
 
 PXR was initially found to interact with the steroid receptor coactivator 1 (SRC-1; 
also known as NCoA-1) [4], a member of the p160 family of coactivators that bind in a 
ligand-dependent manner to nuclear receptors using Leu-X-X-Leu-Leu repeats (where X is 
any amino acid) [52-56].  Crystal structures of several nuclear receptor LBDs in complex 
with coactivator fragments have revealed that binding of ligand induces a conformational 
change in the AF2 region at the C-terminus of the nuclear receptor LBD to create a 
coactivator binding cleft [47, 50, 57-59].  This interaction will be studied in further detail 
later in this review [60].  Other members of the p160 coactivator family known to interact 
with PXR include TIF-2/GRIP-1/NCoA-2 [61] and p/CIP/ACTR/AIBI/TRAM1/RAC3 [24]. 
Binding of a coactivator protein results in the recruitment of basal transcription factors, such 
as CBP (CREB-binding protein)/p300 [53, 62], as well as histone acetyltransferases (HATs) 
that remodel chromatin to enhance transcription [63, 64]. SRC-1 also recruits CARM-1, an 
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arginine methyltransferase that methlyates histone H3 to loosen chromatin for transcription 
[65, 66]. Other coactivators known to interact functionally with PXR include the receptor 
interacting protein RIP140 [67, 68], Suppressor for Gal 1 SUG-1 [67], PPAR binding protein 
PBP [69], and the peroxisome proliferator activating receptor PGC-1 [70].  Several 
transcriptional corepressors that down-regulate gene expression have also been found to bind 
PXR.  Among these are SMRT (Silencing Mediator of Retinoid Thyroid Receptor) [7], 
nuclear receptor corepressor NCoR [7, 69, 71], and, most recently, the small heterodimer 
partner SHP [72].  Unraveling the structural basis of the recruitment of coregulators to NR-
DNA complexes remains a critical area for future study. 
 
MOBILITY IN PXR STRUCTURE 
 
 Several crystal structures of the LBD of PXR have been determined in the unliganded 
(apo) state and in complexes activating ligands and fragments of transcriptional coregulators. 
Published structures include the PXR LBD bound to the cholesterol-lowering drug SR12813, 
both in the presence and absence of SRC-1 peptide, in complex with hyperforin, the 
psychoactive agent found in the herbal antidepressant St. John’s Wort, and in complex with 
the macrolide antibiotic rifampicin [13, 27, 47, 73-75] (Table 1). The overall fold of PXR 
consists of a three-layered α-helical sandwich (α1-α3 / α4-α5-α8-α9 / α7-α10) that encloses 
a large, conformable binding pocket (Figure 1).  A five-stranded anti-parallel β-sheet (β2, β3, 
β4, β1 and β1’) lies adjacent to the ligand binding pocket. This extended β-sheet is unique to 
PXR, as NR LBDs typically contain only two- or three-stranded β-sheets [57, 76-79]. The 
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PXR LBD ends with a short helix (αAF) critical to the AF-2 region of the receptor that 
contacts transcriptional coregulators [27]. 
The α-helical portion of PXR is similar in structure to the NR LBDs described 
previously, with root-mean-square deviations in Cα positions of 1.8-2.9 Å [80-82].  Where 
PXR deviates most significantly in structure, and what likely contributes critically to its 
promiscuous ability to respond to chemically-distinct ligands, is at the bottom of the LBD as 
shown in Figure 1.  The PXRs contain an insert of ~60 residues that is unique in the NR 
superfamily.  This insert, amino acids 177-228 in human PXR, contains not only the β1-β1’ 
regions that extend the PXR β-sheet to five strands, but also a novel α2 that folds along the 
underside of the expansive PXR ligand binding pocket [73]. A portion of this sequence insert 
(residues 178-191) has been disordered in the PXR LBD structures examined to date [13, 27, 
47, 73, 75]. Thus, the PXRs line their ligand binding pockets with novel secondary structural 
elements, including α2 and β1-β1’, many of which are structurally flexible.  
The conformability of key regions of the PXR LBD is critical to the ability of the 
receptor to bind to compounds of varying size and shape. The recent structure of PXR in 
complex with the large macrolide antibiotic rifampicin has provided a direct observation of 
the importance of flexibility in receptor ligand binding.  When the apo (unliganded) structure 
of the PXR LBD was first reported in 2001, it was noted that the receptor’s binding pocket, 
while large, was not large enough to accommodate the established PXR agonist rifampicin 
[27].  The subsequent determination of the PXR-rifampicin complex structure reveals that 
three regions of the LBD become disordered to create the space necessary for this 823 Da 
agonist to bind. These regions are the flexible loop formed by residues 229-235, a mobile 
hydrophobic loop from residues 309-321, and the ~192-210 stretch that is a bona fide helix in 
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some structures, but a partially ordered pseudohelix in others (Figure 2).  Each of these 
regions (indicated in yellow in Figure 2) is highly mobile and exhibits no clear electron 
density in this 2.8 Å resolution crystal structure of the PXR-LBD in complex with rifampicin. 
Similarly, the piperidino group on rifampicin expected to lie next to the ~192-210 loop also 
lacked clear electron density [73].  These observations show that PXR can bind effectively to 
ligands and up-regulate gene expression even when a significant portion of its ligand binding 
pocket is unstructured.  These results also establish that the mobility of regions of PXR that 
are novel in the NR family is vital to the promiscuous ligand binding character of this 
xenobiotic receptor. 
Residues 309-321 were traced as a loop in the apo and in the SR12813 complexes 
[27], but adopt an α-helical structure in complexes with hyperforin, rifampicin, and SR12813 
with the SRC-1 coactivator peptide [13, 47, 73]. This helix, designated α6, is different from 
α6’s found in other nuclear receptors, which are positioned at the bottom of the ligand 
binding cavity in the same region where the ~192-210 residues are located in PXR. Residues 
229-235 support the position of the 192-210 region, and their flexibility mirrors that of the 
longer region nearby. The stretch from about 192 through 210 was pseudohelical in the initial 
apo and SR12813-bound structures, but folded into α2 in the structures of PXR bound to 
hyperforin and the combination of SR12813 and the SRC-1 peptide.  This region of the 
receptor directly contacts bound ligands and changes its position to conform to specific 
ligands; thus, this novel structural motif is central to the ligand binding promiscuity exhibited 
by the PXRs. 
Even when they are not disordered, these regions of the PXR LBD are mobile and 
have been observed to change position to enhance contacts with distinctly shaped ligands. 
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Between the apo and rifampicin-bound structures, for example, the α6, 229-235 and 204-210 
regions of the receptor exhibit main-chain shifts of 1.5 Å, 3.2 Å, and 4.5 Å, respectively, and 
side chain displacements of up to 7 Å (Figure 3).  This conformability allows the ligand 
binding pocket of PXR to expand from 1280 Å3 in volume in the SR12813 complex to more 
than 1600 Å3 in others structures [13, 27, 47, 73].  
In addition to mobility that allows the pocket to accommodate a variety of ligands, 
PXR’s α2 may have another function. It is not clear how ligands enter and exit the ligand 
binding pocket of this promiscuous receptor. In the peroxisome proliferator-activating 
receptors (PPARs) [50, 57], the putative ligand entrance path occurs in a region blocked by 
α6 in PXR. The flexible and untethered α2 may function as a trap-door in PXR, dropping out 
of the way so that ligands can enter the binding pocket. In some PXR structures, a solvent 
accessible channel of up to 3 Å wide and 9 Å long is present in the area adjacent to α2 [13, 
27, 47]. Thus, the sequence motif that contains α2 appears to plays a dual role in receptor 
function: conforming to distinct ligand shapes to enhance promiscuity, and providing a 
dynamic entry and exit pathway for ligand binding and dissociation. 
There are six amino acid side chains that are consistently involved in ligand binding 
in all PXR LBD structures determined to date: three polar residues (Ser-247, Gln-285 and 
His-407) and three hydrophobic residues (Met-243, Trp-299 and Phe-420) (Figure 3) [13, 27, 
47, 73]. The directed promiscuity exhibited by the different species of PXR may partly be 
attributed to changes in these binding residues. For example, the residues Gln-285, His-407 
and Met-243 are not conserved in mouse PXR. This receptor shows a lesser degree of 
promiscuity, and shows no or minimal activity with SR12813, hyperforin or rifampicin 
(Table 1). A similar trend is seen in zebra fish PXR. Alignments of mammalian PXRs reveal 
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that the highest degree of sequence identity occurs between the human and rhesus receptor 
(96%); notably, the same six binding residues are conserved, and both receptors respond 
largely to the same pool of compounds [83].  Differences in diet were originally thought to 
be the driving force for PXR’s directed promiscuity.  It has recently been hypothesized, 
however, that bile acids served as the key evolutionary ligands that drove the receptor’s 
increasing degree of promiscuity over time [84].  
NR LBDs typically contain AF-2 regions that bind to LxxLL motifs in transcriptional 
coactivators, and I/LxxI/VI motifs in corepressors [85].  The structure of the human PXR 
LBD has been determined in complex with the second LxxLL motif of the coactivator SRC-1 
bound to the receptor’s AF-2 region. The LxxLL motif forms an α-helix, with a second short 
helix kinked perpendicular to the first (Figure 4). The leucines in the LxxLL motif pack via 
hydrophobic contacts against the surface of PXR in a groove formed by α3, α4 and αAF. A 
“charge clamp” involving PXR residues Lys-259 and Glu-427 stabilizes the weak helix 
dipole at the C- and N-termini, respectively, of the LxxLL motif [47, 57].  Charged residues 
are conserved in these positions in NR LBDs, and are receptor-coactivator interactions.  
The structure of the PXR LBD in complex with the SR12813 ligand alone revealed 
three distinct binding modes for this small agonist within the receptor’s pocket.  A 
subsequent structure with PXR in complex with both SR12813 and a fragment of SRC-1, 
however, revealed only a single, distinct orientation of the ligand. This observation suggests 
that the PXR LBD “breathes”, allowing small ligands to sample multiple binding modes. In 
the presence of a bound coactivator fragment, however, this sampling motion is restricted, 
resulting in stabilization of the ligand into a single conformation [47].  
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Numerous single-site mutations have been introduced into the PXR LBD with 
varying effects on basal transcriptional activity. Some of these mutations lead to variant 
receptors that exhibit increased basal activation, including H407N, S247W, W299A, and 
R410A [73]. In the S247W mutation, the replacement of serine with a bulky tryptophan 
residue is expected to fill the pocket to mimic ligand binding. This may stabilize coactivator 
interactions and increase basal transcriptional activity. The structural basis for the effects of 
other mutations, however, is less clear.  For example, H407N and W299A may impact 
receptor activity by impairing corepressor binding or by improving coactivator binding. 
Conversely, the mutation of charged residues (R410N, D205A, E321A, and R413A) may 
facilitate increased corepressor or decreased coactivator binding, causing the partial or 
complete loss of basal activation.   
 
AREAS FOR FUTURE STUDY 
 
 In just a few years, PXR has moved from an orphan receptor to an adopted central 
xenobiotic sensor and a putative drug target. We now face new challenges to deepen our 
understanding of PXR’s basic functions in human biology, as well as and how the receptor 
might be harnassed in a clinical setting.  The role that distinct ligands play in PXR’s 
regulation of tissue- and coregulator-specific transcription events is emerging as a key area of 
study for this xenobiotic receptor [86].  In addition, the potential impact of sites of 
phosphorylation on the action and stability of this and other nuclear receptors warrants 
detailed attention [69], as does the pursuit of structures of full-length PXR-RXR 
heterodimers on DNA.  Finally, because PXR is upregulated in certain human cancers [87, 
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88], the search for selective PXR modulators (SPRMs) might provide novel therapeutic tools 
for the treatment of neoplastic and metabolic diseases.   
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FIGURE LEGENDS 
 
Figure 5.1  Structure of the PXR LBD (blue) in complex with the small agonist SR12813 
(red) and a fragment of the SRC-1 transcriptional coactivator (cyan) [47]. The 60-residue 
sequence insert novel to the PXRs and central to the receptor’s promiscuity is highlighted in 
magenta. 
 
Figure 5.2  Close-up of the PXR-LBD bound to the large macrolide antibiotic rifampicin 
(green and red) [73]. Regions of the structure disordered in this complex are highlighted in 
yellow.  The same regions are observed to be mobile in other PXR-LBD structures, and to 
conform to the presence of distinct ligands and bound coactivator fragments. 
 
Figure 5.3 Schematic representation of the ligand binding pocket of human PXR, with 
residues that remain static in structure in bold and those that exhibit <1 Å shifts in position in 
italics.  The side chains of residues that move >1 Å in position are shown, along with the 
magnitude of maximal shifts observed upon ligand binding.  Note that four of the seven 
residues that exhibit a high degree of ligand-induced structural flexibility are part of the 
sequence insert novel to the PXRs. 
 
Figure 5.4   An LxxLL motif of the human coactivator SRC-1 (residues 682-296; 
magenta) bound to the AF-2 region of PXR (white) via a combination of non-polar and 
electrostatic contacts. 
 
Table 5.1   Comparison of human and mouse EC50 values and the key residues contacted 
in crystal structures of PXR complexed with three structurally and chemically disparate 
ligands: SR12813, hyperforin, and rifampicin. 
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Figure 5.2 Close-up of the PXR-LBD bound to the large macrolide antibiotic 
rifampicin (green and red) 
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Figure 5.3 Schematic representation of the ligand binding pocket of human PXR 
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Figure 5.4 An LxxLL motif of the human coactivator SRC-1 bound to PXR 
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Table 5.1 Comparison of human and mouse EC50 values for PXR and ligands 
 
                                                 
1 Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR, Lambert MH, Kliewer SA, Redinbo MR 
2003 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 
42:1430-8 
2 Moore LB, and Redinbo MR, unpublished; N.A. = No Activation. 
3 N.D. = Not Determined 
EC50 
Ligand Structure MW Human 
(nM) 1  
Mouse 
(µM) 
Key 
Structural 
Contacts 
 
SR12813 
 
 
507 
 
32.2 ± 7.7 
 
3.4 ± 1.1 2 
 
Met-
243,Ser247, 
Gln285, Trp-
299 
His407, Phe-
420 
 
Hyperforin 
 
 
537 
 
127  ± 23.4 
 
N.D. 3 
 
Met-
243,Ser247, 
Gln285, Trp-
299 
His407, Phe-
420 
 
Rifampicin 
 
823 
 
463  ± 63.6 1 
 
N.A. 2 
 
Ser208, Met-
243, Ser247, 
Gln285,  Trp-
299, His407,  
Phe-420, 
Arg410   
Chapter 6: 
Computational redesign of a nuclear receptor/coactivator interface to create altered 
binding specificity 
 
INTRODUCTION 
 
The human pregnane X nuclear receptor (PXR) regulates the transcription of a 
number of genes involved in xenobiotic detoxification in the liver and small intestine [1-6]. 
PXR is transcriptionally activated by several coactivators, including ACTR, GRIP, 
PBP/DRIP205, RIP140, and SRC-1 [7, 8].  Coactivators are a limiting factor in transcription 
regulation due to competition for binding by a variety of nuclear receptors, resulting in a 
“squelching” effect on transcription levels.  Squelching leads to transcriptional interference 
between receptors and transcription factors.  The goal of this project was to design mutations 
in both PXR and SRC-1 using a computational protein design program (Rosetta [9]) such that 
they will exclusively interact with one another.  This would effectively eliminate the 
squelching phenomenon and allow for study of a more selective receptor/coactivator 
interaction.  The hypothesis of this proposal is that Rosetta can be used to create mutations at 
the PXR/SRC-1 interface that will alter the binding specificity.  This would generate two 
mutant proteins that could bind to each other with a greater affinity than to their wild-type 
counterparts. 
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Background and Significance 
 
 Nuclear receptors are ligand-regulated transcription factors that play key roles in 
many vital physiological processes such as development, homeostasis, cell growth, 
differentiation, and apoptosis.  Nuclear receptors activate the transcription of target genes in 
a ligand-dependent manner by binding to DNA response elements, usually as homodimers or 
heterodimers with the retinoid X receptor (RXR).  Ligands are diverse in nature and can be 
agonists or antagonists depending upon how binding affects transcription.  They are 
generally small and hydrophobic, and include steroid, thyroid and retinoid hormones, 
vitamins, xenobiotics, and metabolic intermediates [10]. 
 Nuclear receptors require additional factors, termed coregulators, to regulate 
transcription.  Coactivators bind to nuclear receptors in a ligand-dependent manner and 
promote transcription by modifying local chromatin structure and recruiting basal 
transcription factors.  For example, coactivators belonging to the p160/SRC (steroid receptor 
coactivator) family, including SRC-1, possess histone acetyltransferase (HAT) activity [11].  
Hyperacetylated regions of DNA are more actively transcribed than their unacetylated 
counterparts [12].  The p160 family of coactivators possesses three highly conserved LXXLL 
motifs, termed nuclear receptor (NR) boxes, which are necessary for ligand-dependent 
interactions with nuclear receptors [13-18].  These motifs are found repeatedly in many 
coactivators; the LXXLL-containing helix interacts with hydrophobic residues in the AF-2 
helix when it is in the active conformation [19]. 
There are a limited number of coactivators in the cell; because each coactivator can 
bind to more than one type of nuclear receptor, competition occurs [20].  This leads to 
transcriptional interference between receptors and transcription factors (squelching).  Initial 
 163 
evidence for squelching in cotransfection assays was observed in the late 1980’s. Data 
suggested that the overall transcriptional activity of receptors was limited by the available 
cellular pool of coactivators [21, 22].  Following these findings, a yeast two-hybrid screen 
was used to show that SRC-1 interacted with and coactivated almost all of the steroid 
hormone nuclear receptors including the estrogen receptor (ER), progesterone receptor (PR), 
glucocorticoid receptor (GR), thyroid hormone receptor (TR) and RXR [23].  In addition, an 
excess of SRC-1 was found to reverse squelching of transcriptional activity observed 
between PR and ER.  Coexpression of the two receptors reduced the activity of PR by almost 
95%, but subsequent addition of excess SRC-1 reversed this repression 16 fold [23].  It was 
concluded that SRC-1 is a limiting factor for transactivation of steroid hormone nuclear 
receptors.   
It would be beneficial to study the specific interaction between one receptor and 
coactivator by introducing mutations that promote exclusive binding between the two 
species.  Mutation of genes encoding mutant nuclear receptors and coactivators could be used 
to regulate expression of enzymes involved in metabolism of steroids, carbohydrates, lipids, 
and xenobiotics.  This could have interesting therapeutic applications in vivo.  The goals of 
this project were to use the computational protein design program Rosetta to redesign the 
PXR/SRC-1 interface to generate an altered binding specificity, to test this redesign through 
the use of site-directed mutagenesis and binding characterization, and to determine the 
crystal structures of complexes of forms of mutant PXR and mutant SRC-1 peptides. 
 
COMPUTATIONAL PROTEIN REDESIGN OF PXR/SRC-1 INTERFACE USING 
ROSETTA 
 164 
 
The possibility of computational protein design was first considered in the early 
1980’s [24, 25].  Research confronted the daunting task of predicting a three dimensional 
protein structure based solely on amino acid sequence.  Eventually it was concluded that it 
would be more feasible to tackle the opposite problem—designing a de novo sequence that 
would fold into a desired 3-D structure [26].  Protein design was concentrated on assigning 
energy values to the various types of naturally occurring residue interactions.  The first fully 
automated protein was not designed until 1997.  Nearly 2.0 × 1027 possible amino acid 
sequences from a combinatorial library were screened based on physical chemical potential 
functions and spatial restraints to find a sequence that would fold into the desired target 
motif, a zinc-finger fold [27].   
Rosetta is a computational program that redesigns given protein sequences using a 
Monte Carlo optimization procedure.  By altering both the position and character of amino 
acid residues at random positions using a Protein Data Bank-compiled rotamer database, a 
minimum energy structure can be obtained.  Rosetta uses an energy function with several 
different parameters.  Key features of the function are a Lennard-Jones potential relating to 
interatomic distance, a hydrogen bonding potential, an implicit solvation model which 
penalizes the burial of hydrophilic residues, and an amino acid rotamer database.  These 
features are often found in protein design functions. 
 
Methods 
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 Rosetta was used to assign an energy value to the wild-type PXR/SRC-1 complex as 
well as the individual proteins.  The interface was carefully examined to determine the most 
important interactions between amino acid residues.  We chose to alter a highly conserved 
leucine in one of the NR box motifs in SRC-1 to an alanine, and several interacting PXR 
residues were selected for alteration by the program.  Altered specificity can be determined 
as follows: Let wtPXR=A, mutant PXR=A’, wtSRC-1=B, and mutant SRC-1=B’; 
EA’B’ - EA’ - EB’ = ∆ EA’B’     (eq. 1) 
EA’B - EA’ - EB = ∆ EA’B       (eq. 2) 
EAB’ - EA - EB’ = ∆ EAB’ (eq. 3) 
When ∆ EA’B’ is greater than both ∆ EA’B and ∆ EAB’ (i.e. the energy of the two-mutant 
species is more favorable than the energy of any wild-type-mutant combination), altered 
specificity has been achieved. 
 
Results 
 
 Two residues on PXR were altered (I255L, L276A); a highly conserved leucine from 
an LXXLL motif on SRC-1 (L694A) was also altered.  The energy values of the various 
complexes are shown in Table 1 and indicate that altered specificity was achieved.  Figure 
6.2 shows the superposition of the wild-type and mutant protein complexes.  Clearly the 
integrity of packing is maintained in the mutant; in fact, the backbone of the proteins remains 
rigid throughout the simulation.  Only the side chains are permitted to move or change. 
 In a study of nine globular proteins completely redesigned by Rosetta, denaturation 
experiments showed that eight of these proteins were folded, and six had stabilities equal to 
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or greater than their wild-type counterparts [28].  Additionally, Rosetta was recently used to 
design a globular protein with a novel fold, the structure of which was confirmed using x-ray 
crystallography [29].  The root mean square deviation between the actual and predicted 
structures was 1.2 Ǻ.  These results provide strong evidence that computational design 
methods do have the ability to identify stable amino acid sequences.   
  
DETERMINATION OF BINDING CONSTANTS FOR REDESIGNED PXR/SRC-1 
COMPLEX  
 
The mutant PXR/mutant SRC-1 complex designed above was expected to have a 
smaller dissociation constant (KD) than the wild-type complex, which is indicative of a 
greater affinity as predicted by Rosetta.  Surface Plasmon Resonance (SPR) was used to 
obtain these binding constants. 
 
Methods 
 
Residues 130-434 of the human PXR LBD with an N-terminal polyhistidine tag were 
subcloned into the pRSETA expression vector (Invitrogen, Carlsbad, CA), and residues 623-
710 of hSRC-1 protein were subcloned into the pACYC184 bacterial vector (American Type 
Culture Collection 37033).  These plasmids were cotransformed into the BL21(DE3) strain 
of E. coli and expressed at 22°C without IPTG induction for 24 hours.  Cotransformation of 
PXR and SRC-1 was necessary for the stable expression of the protein.  The PXR-SRC-1 
complex was purified using ProBond nickel-chelating resin (affinity) (Invitrogen, Carlsbad, 
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CA) and subsequently by SP Sepharose Fast Flow resin (cation exchange) (Pharmacia, 
Uppsala, Sweden) [30].  Protein was concentrated to 0.67 mg/mL at 4ºC using an Amicon 
YM-10 unit (Millipore, Billerica, MA).  Concentration took place in the presence of a 10-
fold molar excess of the cholesterol-lowering drug SR12813, a known activator of PXR, in 
order to increase the stability of the protein and promote coactivator binding.   
Mutant PXR plasmid DNA was obtained using the Quik-Change Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) as instructed by the manual.  Mutations were 
confirmed by sequencing, and expression and purification were carried out as previously 
described to a final concentration of 0.5 mg/mL. 
 Biotinylated SRC-1 peptide (residues 682-696 containing a LXXLL motif) (SynPep, 
Dublin, California) was immobilized on a streptavadin (SA) sensor chip (Biacore, Uppsala, 
Sweden).  PXR in SPR buffer (0.01 M HEPES, pH 7.4) at varying concentrations (3-10 µM) 
was passed over the peptide in order to obtain an association curve.  Excess buffer was then 
used to reverse protein binding and obtain a dissociation curve.  This was done for wild-type-
wild-type and one wild-type-mutant combination of SRC-1 and PXR, respectively.   
 Since PXR must be coexpressed with SRC-1, the protein we used in the experiment 
was actually a complex of PXR and SRC-1. This presented a problem in that we were trying 
to determine a binding affinity for the complex.  It has been shown previously that 
concentration of hPXR/SRC-1 with excess peptide displaces the larger SRC-1 fragment. This 
was confirmed by subsequent crystallization and structure determination [19].  
Immobilization of the excess SRC-1 peptide on the sensor chip should displace the larger, 
expressed SRC-1 complex and allow for accurate determination of a binding constant.  It was 
assumed that the association curve generated in the experiment would not be affected by this 
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displacement.  To prove this was the case, fractions of protein containing only PXR without 
SRC-1 were identified as they eluted from the ion-exchange column by using SDS-PAGE.  
These fractions were then pooled and concentrated for use in SPR experiments, and gave 
similar results to the ones described. 
 
Results 
 
 The binding curves for wild-type PXR and wild-type SRC-1 peptide are shown in 
Figure 6.3.  The dissociation constant KD was calculated using BiaEvaluation 3.0 (Biacore, 
Uppsala, Sweden) by fitting the curves to a 1:1 Langmuir binding model using the equation 
KD = kd/ka, the acquired association and dissociation rate constants.  The dissociation constant 
between PXR and SRC-1 peptide was determined to be 0.9 µM.  This value is well within the 
range of other literature values of NR/coactivator binding constants [31]. 
 Unfortunately, the binding curves for the mutant PXR and wild-type SRC-1 were not 
intelligible enough to produce a usable binding constant.  The protein itself did not express as 
well as the wild-type and also behaved in a more unstable manner.  The problem arose when 
the protein could not be flushed off of the bound SRC-1 in order to acquire a dissociation 
curve.  This led us to believe that the protein was structurally unstable, causing non-specific 
binding to both the attached SRC-1 peptide and the sensor chip, and therefore we were not 
able to determine a binding constant.
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FIGURE LEGENDS 
 
Figure 6.1  Crystal structure of the PXR LBD in complex with the cholesterol-lowering 
drug SR12813 and SRC-1 peptide.  The ligand is shown in blue and the coactivator is shown 
in cyan. 
 
Figure 6.2 Wild-type PXR is shown in purple and wild-type SRC-1 is shown in green.  
The L694F SRC-1 mutation is shown in yellow, while the I255L and L276A PXR mutations 
are shown in magenta.  Residues in blue were subject to rotamer shifts. 
 
Figure 6.3 The plot shows the association and dissociation of varying concentrations of 
wild-type PXR with bound SRC-1.  A 1:1 Langmuir binding model was fit to this data to 
give a dissociation constant of 0.9 µM. 
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Figure 6.1  Structure of PXR-SR12813-SRC-1 complex 
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Figure 6.2  Overlay of wild-type PXR/SRC-1 complex with mutant 
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Figure 6.3 Response curve of wild-type PXR binding to SRC-1 
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 ∆EAB 
 
∆EA’B’ ∆EA’B 
 
∆EAB’ 
 
Native Sequences -14.7    
Design   -13.9 958.5 -9.2 
 
Table 6.1  Energy values of all four wild-type and mutant complexes. 
 
 
 
